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tion . 
HUMANIZED PERTUSSIS ANTIBODIES AND Further , in the developing world , access to the existing 
USES THEREOF pertussis vaccine , however flawed , is inconsistent and often 
difficult . 
CROSS - REFERENCES TO RELATED Naturally occurring antibodies are multimeric proteins 
APPLICATIONS 5 that contain four polypeptide chains . Two of the polypeptide 
chains are called heavy chains ( H chains ) , and two of the 
This application is a divisional application of U . S . appli - polypeptide chains are called light chains ( L chains ) . The 
cation Ser . No . 14 / 675 . 514 . filed Mar . 31 . 2015 . which immunoglobulin heavy and light chains are connected by an 
claims the benefit of U . S . Provisional Appl . No . 61 / 973 , 141 , interchain disulfide bond . The immunoglobulin heavy 
filed Mar . 31 , 2014 , and U . S . Provisional Appl . No . 62 / 046 , 621046 10 chains are connected by interchain disulfide bonds . A light chain consists of one variable region ( V ) and one constant 403 , filed Sep . 5 , 2014 , the content of each of which is 
incorporated herein by reference in its entirety and for all region ( CL ) . The heavy chain consists of one variable region ( V ) and at least three constant regions ( CH , , CH , and purposes . CHZ ) . The variable regions determine the specificity of the 
STATEMENT AS TO RIGHTS TO INVENTIONS 15 antibody . Each variable region comprises three hypervari 
MADE UNDER FEDERALLY SPONSORED able regions also known as complementarity determining regions ( CDRs ) flanked by four relatively conserved frame RESEARCH OR DEVELOPMENT work regions ( FRS ) . The three CDRs , referred to as CDR , 
CDR2 , and CDR3 , contribute to the antibody binding speci 
This invention was made with government support under 20 ficity . Naturally occurring antibodies have been used as 
Grant No . R21 A1066239 awarded by the National Institutes starting material for engineered antibodies , such as human 
of Health . The Government has certain rights in the inven ized antibodies . 
Antibodies that bind the pertussis toxin protein have been 
developed , but the effectiveness of these antibodies in 
REFERENCE TO A “ SEQUENCE LISTING , ” A 25 patients is either minimal or unclear . There remains a need 
TABLE , OR A COMPUTER PROGRAM LISTING for improved antibodies against the pertussis toxin protein 
APPENDIX SUBMITTED AS AN ASCII FILE with increased efficacy and reduced sides effects to be used 
as therapeutics . 
The Sequence Listing written in file 48932 
522D01US _ ST25 . TXT , created on Nov . 7 , 2016 , 26 , 517 30 SUMMARY 
bytes , machine format IBM - PC , MS Windows operating 
system , is hereby incorporated by reference . Accordingly , in various aspects , the present invention is 
directed to one or more humanized antibodies that bind to 
FIELD OF THE INVENTION and / or neutralize a pertussis toxin protein and the uses of the 
35 same in the treatment or prevention of pertussis . 
The present invention relates , in part , to humanized In one aspect , the present invention is directed to a 
antibodies which bind the pertussis toxin protein and their humanized 1B7 antibody that binds a pertussis toxin protein . 
use as therapeutic agents . In particular , the present invention The humanized 1B7 antibody includes an immunoglobulin 
is directed to , in part , humanized antibodies derived from heavy chain variable region and an immunoglobulin light 
murine antibodies 1B7 and 11E6 which bind the pertussis 40 chain variable region . In various embodiments , the human 
toxin protein . ized 1B7 antibody includes an immunoglobulin heavy chain 
variable region comprising an amino acid sequence selected 
BACKGROUND from SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID NO : 3 , SEQ ID 
NO : 4 , SEQ ID NO : 5 , and SEQ ID NO : 6 , and an immuno 
Bordetella pertussis ( B . pertussis ) is a gram - negative 45 globulin light chain variable region comprising an amino 
bacterium that infects the upper respiratory tract , causing acid sequence selected from SEQ ID NO : 7 , SEQ ID NO : 8 , 
uncontrollable , violent coughing . According to the World SEQ ID NO : 9 , SEQ ID NO : 10 , SEQ ID NO : 11 , and SEQ ID 
Health Organization , B . pertussis infection causes an esti - NO : 12 . 
mated 300 , 000 deaths worldwide each year , primarily In another aspect , the present invention is directed to a 
among young , unvaccinated infants . Infants with pertussis 50 humanized 11E6 antibody that binds a pertussis toxin pro 
often require hospitalization in pediatric intensive care units , tein . The humanized 11E6 antibody includes an immuno 
and their treatments frequently involve mechanical ventila - globulin heavy chain variable region comprising an amino 
tion . Pertussis in adults generally leads to a chronic cough acid sequence selected from SEQ ID NO : 13 , SEQ ID 
referred to as the " cough of 100 days . ” The incidence of NO : 14 , SEQ ID NO : 15 , SEQ ID NO : 16 , SEQ ID NO : 17 , 
pertussis is increasing due to exposures of unvaccinated and 55 and SEQ ID NO : 18 , and an immunoglobulin light chain 
under - vaccinated individuals including infants who are not variable region comprising an amino acid sequence selected 
yet fully vaccinated , individuals whose immunity has dimin - from SEQ ID NO : 19 , SEQ ID NO : 20 , SEQ ID NO : 21 , SEQ 
ished over time , and asymptomatic carriers . ID NO : 22 , SEQ ID NO : 23 , and SEQ ID NO : 24 . 
Recent news reports throughout the United States indicate în various embodiments , the humanized 1B7 and 1156 
that the pertussis vaccine introduced in the 1990s does not 60 antibodies show improved properties . In an embodiment , the 
provide long - term protection . There is no approved treat - humanized 1B7 antibody binds the pertussis toxin protein 
ment for pertussis . Antibiotic treatments do not have a major with a Ky of less than about 3 nM , or about 2 nM , or about 
effect on the course of pertussis , because while the treatment 1 nM , or about 0 . 5 nM . In another embodiment , the human 
can eliminate the B . pertussis bacteria from the respiratory ized 11 E6 antibody binds the pertussis toxin protein with a 
tract , it does not neutralize the pertussis toxin protein . 65 K , of less than about 12 nM , or about 10 nM , or about 8 nM , 
Accordingly , there remains a need for more effective thera - or about 6 nM , or 4 nM , or 2 nM , or about 1 nM , or about 
pies against pertussis . 0 . 5 nM . 
US 10 , 035 , 846 B2 
In various embodiments , the present invention also pro FIGS . 6A - 6D show thermal unfolding plotted as Tem 
vides nucleic acids , expression vectors , host cells , and perature ( ° C . ) vs . Fluorescence for a humanized hu11E6 
methods for making the humanized 1B7 and 11E6 antibod antibody , a humanized hulB7 antibody , a murine m11E6 
ies . The present invention also provides pharmaceutical antibody , and a murine m1B7 antibody . FIG . 6A shows 
compositions comprising the humanized 1B7 and / or 11E6 5 thermal unfolding for the hu11E6 antibody ( hu11E6 - 15x ) . 
antibodies . The top line corresponds to 10 uM hu11E6 - 15x , the second 
In one aspect , the method of the invention involves line from the top corresponds to 20 uM hu11E6 - 15x , the 
treating a patient with Bordetella pertussis , comprising second line from the bottom corresponds to 5 uM hu11E6 
administering to the patient the humanized 1B7 antibody 15x , and the bottom line corresponds to PBS . FIG . 6B shows 
and / or the humanized 11E6 antibody , or pharmaceutical 10 thermal unfolding for the hulB7 antibody . The top line 
compositions including the antibody or antibodies . In an corresponds to 20 uM hu1B7 , the second line from the top 
embodiment , the humanized 1B7 antibody and the human - corresponds to 10 uM hu1B7 , the second line from the 
ized 11E6 antibody are co - administered to the patient pro - bottom corresponds to 5 uM hu1B7 , and the bottom line 
ducing synergistic effects . In another embodiment , the corresponds to PBS . FIG . 6C shows thermal unfolding for 
method includes administering to the patient the humanized 15 the m11E6 antibody . The top line corresponds to 3 UM 
1B7 antibody and / or the humanized 11E6 antibody , along m11E6 , the second line from the top corresponds to 1 . 5 uM 
with antimicrobial agents . In a further embodiment , the m11E6 , the second line from the bottom corresponds to 0 . 75 
method of the invention is directed to preventing Bordetella uM m11E6 , and the bottom line corresponds to PBS . FIG . 
pertussis infection in a subject by administering to the 6D shows thermal unfolding for the m1B7 antibody . The top 
subject the humanized 1B7 antibody and / or the humanized 20 line corresponds to 3 uMm1B7 , the second line from the top 
11E6 antibody , or pharmaceutical compositions including corresponds to 1 . 5 uM m1B7 , the second line from the 
the antibody or antibodies . bottom corresponds to 0 . 75 uM m1B7 , and the bottom line 
In some embodiments , the method of the invention corresponds to PBS . 
involves preventing the onset of pertussis by preventatively FIG . 7 shows the results of a Pertussis Toxin ( PTx ) ELISA 
administering the humanized 1B7 antibody and / or the 25 assay which compares the PTx binding affinities of human 
humanized 11E6 antibody , or pharmaceutical compositions ized hu1B7 and hu11E6 antibodies versus the mouse m1B7 
including the antibody or antibodies for a patient , including and m11E6 antibodies . Results are shown as antibody con 
an infant that has yet to be vaccinated . centration ( nM ) vs . normalized absorbance . 
In one embodiment , the method of the invention com FIG . 8 shows the results of a Competition ELISA assay 
prises reducing white blood cell count in the patient . In 30 which determines the PTx binding affinities of the human 
another embodiment , the method of the invention comprises ized hu1B7 and hu11E6 antibodies as produced in two 
reducing the duration and / or the frequency of cough in the different laboratories . Results are shown as PTx concentra 
patient . In a further embodiment , the method of the inven - tion vs . absorbance . 
tion comprises reducing the levels of the Bordetella pertus FIG . 9 shows the results of a CHO cell in vitro protection 
sis in the nasopharynx and the lung of the patient . In another 35 assay that measures the ability of the humanized hu1B7 and 
embodiment , the method of the invention neutralizes the hu11E6 antibodies to neutralize the pertussis toxin protein . 
pertussis toxin protein . Results as shown in molar ratios ( mol mAb / mol PTx ) . 
In another aspect , the method of the invention involves FIG . 10 shows the results of a PTx toxin ELISA assay 
treating a patient with Bordetella parapertussis , comprising along with the EC50 ( ug / mL ) values for a mixture of the 
administering to the patient the humanized 1B7 antibody 40 humanized hu1B7 and hu11E6 antibodies . The antibodies 
and / or the humanized 11E6 antibody , or pharmaceutical were mixed and stored at 4° C . for 1 minute , 1 hour , and 22 
compositions including the antibody or antibodies . In hours . Results are shown as antibody concentration ( ug / mL ) 
another aspect , the method of the invention is directed to vs . normalized absorbance . 
preventing Bordetella parapertussis infection in a subject by FIG . 11 demonstrates the elimination ( B ) half - lives ( t1 / 2B ) 
administering to the subject the humanized 1B7 antibody 45 of a humanized hu11E6 antibody , a humanized hu1B7 
and / or the humanized 11E6 antibody , or pharmaceutical antibody , and a mixture of the humanized hulB7 and 
compositions including the antibody or antibodies . humanized hu11E6 antibodies . All half - lives were deter 
Other aspects and embodiments of the invention will be mined in mice . 
apparent from the following detailed description and FIG . 12 shows the results of a PTx toxin ELISA assay 
examples . 50 which determines the effects of heat treatment on the activity 
of the humanized hu1B7A antibody . Specifically , 50 ug / mL 
DESCRIPTION OF THE DRAWINGS of the antibody were incubated in PBS for 30 minutes on ice , 
at 50° C . , or at 70° C . , and quenched on ice for 1 minute . The 
FIG . 1 shows a SDS PAGE gel of a humanized hu1B7 results are measured as antibody concentration ( ug / mL ) vs . 
antibody under reducing and non - reducing conditions . 55 absorbance . 
FIG . 2 shows size exclusion chromatography of a human - FIG . 13 shows the results of a PTx toxin ELISA assay 
ized hu1B7 antibody . which determines the effects of heat treatment on the activity 
FIG . 3 shows a SDS PAGE gel of a humanized hu11E6 of the humanized hul1E6A antibody . Specifically , 50 ug / mL 
antibody under reducing and non - reducing conditions . of the antibody were incubated in PBS for 30 minutes on ice , 
FIG . 4 shows size exclusion chromatography of a human - 60 at 50° C . , or at 70° C . , and quenched on ice for 1 minute . The 
ized hullE6 antibody . results are measured as antibody concentration ( ug / mL ) vs . 
FIG . 5 shows size exclusion chromatography of , from left absorbance . 
to right , a humanized hu1B7A antibody ( third line ) , FIG . 14 shows the results of a PTx toxin ELISA assay 
hu11E6A ( first line ) , and a mixture of the two antibodies along with the EC ( ug / mL ) values for a humanized 
( second line ) . The results are measured in mL vs . mAu , and 65 hu1B7A antibody , a humanized hu11E6A antibody and a 
all lines are in comparison to the expected molecular weight mixture of the two antibodies . Results are shown as antibody 
( MW , perpendicular black line ) . concentration ( ug / mL ) vs . normalized absorbance . 
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FIG . 15 shows the efficacy of the humanized 11E6 and chain antibodies ( e . g . , scFv ) , minibodies and diabodies . An 
1B7 antibodies in treating mice infected with the B . pertussis antibody conjugated to a toxin moiety is an example of a 
D420 strain ( as measured by % weight gain ) . Mice were 
treated with either PBS , P - IVIG , a murine m1B7 antibody , Antibodies that Bind the Pertussis Toxin Protein Antibodies that Bind the Pertussis Toxin Protein a ch1B7 antibody , a humanized hu1B7 antibody , a murine 5 
m11E6 antibody , a ch11E6 antibody , a humanized hullE6 In one aspect , the present invention is directed to a 
antibody , or a mixture of humanized hu1B7 and hu11E6 humanized 1B7 antibody and a humanized 11E6 antibody 
antibodies , and their body weight was measured at 10 days that bind a pertussis toxin protein . In various embodiments , 
post post - infection . Uninfected naive mice served as base a humanized antibody is a non - human antibody that has 
line control . 10 been altered to increase its similarity to a human antibody . 
FIGS . 16A and 16B show the efficacy of the humanized In some embodiments , a humanized antibody is a geneti 
11E6 and 1B7 antibodies in treating mice infected with the cally engineered antibody in which at least one CDR ( or 
B . pertussis D420 strain ( as measured by leukocyte count functional fragment thereof ) from a non - human , e . g . mouse , 
per 50 uL of blood ) . Mice were treated with either PBS , antibody ( “ donor antibody ” , which can also be rat , hamster 
P - IVIG , a murine m1B7 antibody , a ch1B7 antibody , a 15 or other non - human species ) is grafted onto a human anti 
humanized hu1B7 antibody , a murine m11E6 antibody , a body ( " acceptor antibody ” ) . In some embodiments , more 
ch11E6 antibody , a humanized hul1E6 antibody , or a mix - than one mouse CDR is grafted ( e . g . , all six mouse CDRs are 
ture of humanized hu1B7 and hu11E6 antibodies , and their grafted ) . The sequence of the acceptor antibody can be , for 
blood leukocyte count was evaluated at 3 days and 10 days example , a mature human antibody sequence ( or fragment post infection . Uninfected naive mice served as baseline 20 thereof ) , a consensus sequence of a human antibody 
control . sequence ( or fragment thereof ) , or a germline region FIG . 17 shows the efficacy of the humanized 11E6 and 
1B7 antibodies in reducing the colonization of mouse lungs sequence ( or fragment thereof ) . Thus , in some embodi 
by the B . pertussis bacteria . ments , a humanized antibody may be an antibody having 
FIGS . 18A and 18B show the therapeutic effect of a 25 25 one or more CDRs from a donor antibody and variable 
cocktail of the humanized U1E6 and 137 antibodies on B . region framework ( FR ) . The FR may form part of a constant 
pertussis infected baboons . Specifically , white blood cell region within a human antibody . 
counts and cough counts were assessed . In addition , in order to retain high binding affinity , amino 
FIG . 19 shows the pathology sections from the lungs of B . acids in the human acceptor sequence may be replaced by 
pertussis infected baboons that were treated with the human - 30 the corresponding amino acids from the donor sequence , for 
ized 11E6 and 1B7 antibodies . example where : ( 1 ) the amino acid is in a CDR ; ( 2 ) the 
FIGS . 20A and 20B show the therapeutic effect of a amino acid is in the human framework region ( e . g . , the 
cocktail of the humanized 11 E6 and 1B7 antibodies on B . amino acid is immediately adjacent to one of the CDR ' s ) . 
pertussis infected baboons . Specifically , white blood cell See , U . S . Pat . Nos . 5 , 530 , 101 and 5 , 585 , 089 , incorporated 
counts and nasal wash bacterial counts were assessed . 35 herein by reference , which provide detailed instructions for FIGS . 21A and 21B show the antibody serum concentra construction of humanized antibodies . Indeed , this selection tion and antibody half - life , respectively , of the humanized of residues in , for example , the human framework region is 11E6 and 1B7 antibodies in two B . pertussis infected often central to a humanized antibodies desirability . baboons ( i . e . , baboon # 12913 and 15913 ) . The timing shown 
on the Y - axis of FIG . 21 A is as shown in FIGS . 20 A and 20B 40 Although humanized antibodies often incorporate all six 
( i . e . infection at time = 0 , treatment at 3 days ) . CDRs ( e . g . , as defined by Kabat , but often also including 
hypervariable loop H1 as defined by Chothia ) from a mouse 
DETAILED DESCRIPTION antibody , they can also be made with fewer mouse CDRs 
and / or less than the complete mouse CDR sequence ( e . g . a 
The present invention is based , in part , on the discovery 45 functional fragment of a CDR ) . 
of humanized 1B7 and 11E6 antibodies that exhibit In various embodiments , the humanized light chain vari 
improved biological activities . Because of the binding and / able region is fused to a light chain constant region ( e . g . or neutralizing activity of these antibodies against the per human kappa or a lambda light chain ) . In various embodi tussis toxin protein , they are useful for treating patients ments , the humanized heavy chain variable region is fused infected with the Bordetella pertussis bacteria . The dis - 50 
closed antibodies are engineered to target the pertussis toxin to a heavy chain constant region , including various allotypes and isotypes of each . For example , the heavy chain constant protein with high specificity while causing minimal side 
effects in patients . Furthermore , the disclosed antibodies region can be derived from any immunoglobulin type ( e . g . 
exhibit enhanced stability and long in vivo half - lives . Vari IgG , IgM , IgA , IgD , or IgE ) . In some embodiments , IgG is 
ous features and aspects of the invention are discussed in 55 used . For IgG , the constant region can come from IgG1 , 
more detail below . IgG2 , IgG3 , or IgG4 . In some embodiments , IgG1 is used . 
As used herein , unless otherwise indicated , the term Moreover , there are many isotypes of each IgG that can be 
" antibody ” means an intact antibody ( e . g . , an intact mono chosen , some are naturally occurring and some are deriva 
clonal antibody ) or antigen - binding fragment of an antibody tives of naturally occurring isotypes . The type of IgG that is 
( eg an antigen - binding fragment of a monoclonal anti - 60 chosen will determine the effector functions of the antibody 
body ) , including an intact antibody or antigen - binding frag - ( e . g . opsonophagocytosis , complement fixation , etc . ) . 
ment that has been modified , engineered or chemically In one aspect , the present invention is directed to a 
conjugated , or that is a human antibody . Examples of humanized 1B7 antibody that binds a pertussis toxin protein , 
antibodies that have been modified or engineered are chi - and comprises an immunoglobulin heavy chain variable 
meric antibodies , humanized antibodies , and multispecific 65 region and an immunoglobulin light chain variable region . 
antibodies ( e . g . , bispecific antibodies ) . Examples of antigen - The immunoglobulin heavy chain variable region comprises 
binding fragments include Fab , Fab ' , F ( ab ' ) 2 , Fv , single an amino acid sequence selected from : 
m 
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- continued 
1B7 : 
( SEQ ID NO : 1 ) 
OVOLOOPGSELVRPGASVKLSCKASGYKFTSYWMHWVKORPGOGLEWIG 
sdr1B7 : 





( SEO ID NO : 2 ) 
OVOLVOSGAEVKKPGASVKVSCKASGYKFTSYWMHWVROAPGOGLEWIG 
fra187 : 






( SEQ ID NO : 3 ) 
QVOLVOSGAEVKKPGASVKVSCKASGYKFTSYWMHWVRQAPGQGLEWIG 
ven137 : 






Any one of the disclosed 1B7 heavy chains can be paired 
sdr167 : with any of the disclosed 137 light chains . By way of 
( SEQ ID NO : 4 ) illustration , the following pairs can be incorporated into an 
QVOLVOSGAEVKKPGASVKVSCKASGYKFTSYWMHWVRQAPGQGLEWIG 25 antibody of the present compositions and methods : SEQ ID 
NIFPGSGSTNYAQKFOGRVTLTVDTSTSTAYMELSSLRSEDTAVYYCTR NO : 1 / SEQ ID NO : 7 , SEQ ID NO : 1 / SEQ ID NO : 8 ; SEQ ID NO : 1 / SEO ID NO : 9 ; SEO ID NO : 1 / SEO ID NO : 10 ; 
WLSGAYFDYWGQGTTVTVSS SEO ID NO : 1 / SEO ID NO : 11 ; SEO ID NO : 1 / SEO ID NO : 
12 ; SEQ ID NO : 2 / SEQ ID NO : 7 ; SEQ ID NO : 2 / SEQ ID 
fra1B7 : 30 NO : 8 ; SEQ ID NO : 2 / SEQ ID NO : 9 ; SEQ ID NO : 2 / SEQ 
( SEQ ID NO : 5 ) ID NO : 10 ; SEQ ID NO : 2 / SEQ ID NO : 11 ; SEQ ID NO : 
QVQLQQSGSELKKPGASVKISCKASGYKFTSYWMHWVKORPGQGLEWIG 2 / SEO ID NO : 12 ; SEQ ID NO : 3 / SEQ ID NO : 7 ; SEQ ID 
NO : 3 / SEQ ID NO : 8 ; SEQ ID NO : 3 / SEQ ID NO : 9 ; SEQ 
NIFPGSGSTNYDEKFNSRVTLTVDTSTSTAYMELSSLRSEDTAVYYCTR ID NO : 3 / SEO ID NO : 10 ; SEO ID NO : 3 / SEO ID NO : 11 ; 
35 SEQ ID NO : 3 / SEQ ID NO : 12 ; SEQ ID NO : 4 / SEQ ID NO : WLSGAYFDYWGQGTTLTVSS 7 ; SEQ ID NO : 4 / SEQ ID NO : 8 ; SEQ ID NO : 4 / SEQ ID 
NO : 9 ; SEQ ID NO : 4 / SEQ ID NO : 10 ; SEQ ID NO : 4 / SEQ ven1B7 : 
( SEO ID NO : 6 ) ID NO : 11 ; SEQ ID NO : 4 / SEQ ID NO : 12 ; SEQ ID NO : 
QVOLVQSGAELVKPGASVKLSCKASGYKFTSYWMHWVKORPGQGLEWIG 5 / SEQ ID NO : 7 ; SEQ ID NO : 5 / SEQ ID NO : 8 ; SEQ ID 
40 NO : 5 / SEQ ID NO : 9 ; SEQ ID NO : 5 / SEQ ID NO : 10 ; SEQ 
NIFPGSGSTNYDEKFNS KATLTVDTSTSTAYMELSSLRSEDTAVYYCTR ID NO : 5 / SEQ ID NO : 11 ; SEQ ID NO : 5 / SEQ ID NO : 12 ; 
SEQ ID NO : 6 / SEQ ID NO : 7 ; SEQ ID NO : 6 / SEQ ID NO : 
WLSGAYFDYWGOGTTLTVSS 8 ; SEQ ID NO : 6 / SEQ ID NO : 9 ; SEQ ID NO : 6 / SEQ ID 
The immunoglobulin light chain variable region com - 15 G / SEO ID NO : 12 NO : 10 ; SEQ ID NO : 6 / SEQ ID NO : 11 ; and SEQ ID NO : 
prises an amino acid sequence selected from : In one embodiment , the humanized 1B7 antibody com 
prises an immunoglobulin heavy chain variable region com 
prising the amino acid sequence of SEQ ID NO : 2 , and an 1B7 : 
( SEQ ID NO : 7 ) immunoglobulin light chain variable region comprising the 
QIVLTOSPALMSASPGEKVTMTCSASSSVSFMYWYQQKPRSSPKPWIY 50 amino acid sequence of SEQ ID NO : 8 . 
In one embodiment , the humanized 1B7 antibody com LTSNLPSGVPARFSGSGSGTSYSLTISSMEAEDAATYYCOOWSSHPPT prises an immunoglobulin heavy chain variable region com 
FGSGTKLEIK prising the amino acid sequence of SEQ ID NO : 3 , and an 
immunoglobulin light chain variable region comprising the 
cdr1B7 : 55 amino acid sequence of SEQ ID NO : 9 . ( SEQ ID NO : 8 ) 
QIVLTQSPDFQSVTPKEKVTITCSASSSVSFMYWYOQKPDOSPKPLIY In one embodiment , the humanized 1B7 antibody com prises an immunoglobulin heavy chain variable region com 
LTSNLPSGVPARFSGSGSGTSYTLTINSLEAEDAATYYCOQWSSHPPT prising the amino acid sequence of SEQ ID NO : 4 , and an 
immunoglobulin light chain variable region comprising the 
FGSGTKVEIK 60 amino acid sequence of SEQ ID NO : 10 . 
abb1B7 : In one embodiment , the humanized 1B7 antibody com 
( SEQ ID NO : 9 ) prises an immunoglobulin heavy chain variable region com 
QIVLTOSPDFOSVTPKEKVTITCRASSSVSFMYWYOQKPDQSPKPLIY prising the amino acid sequence of SEQ ID NO : 5 , and an 
immunoglobulin light chain variable region comprising the LTSNLPSGVPARFSGSGSGTDYTLTINSLEAEDAATYYCOOWSSHPPT 
65 amino acid sequence of SEQ ID NO : 11 . 
FGSGTKVEIK In one embodiment , the humanized 1B7 antibody com 
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10 
prising the amino acid sequence of SEQ ID NO : 6 , and an - continued 
immunoglobulin light chain variable region comprising the 
amino acid sequence of SEQ ID NO : 12 . abb11E6 : ( SEQ ID NO : 15 ) 
In other embodiments , the humanized 1B7 antibody com EVOVVESGGGLVOPGRSLRLSCTTSGFTFTDYYVSWVRQAPGKALEWVGF 
prises an immunoglobulin heavy chain variable region com 
prising an amino acid sequence having at least about 50 % IRNKVNGYTTEFAASVRGRFTISRDNSKSILYLQMNSLKIEDTAVYYCAR 
identity , about 51 % identity , about 52 % identity , about 53 % VSYYGRGWYFDYWGQGTTVTVSS identity , about 54 % identity , about 55 % identity , about 56 % 
identity , about 57 % identity , about 58 % identity , about 59 % 10 
identity , about 60 % identity , about 61 % identity , about 62 % ( SEQ ID NO : 16 ) 
identity , about 63 % identity , about 64 % identity , about 65 % EVQVVESGGGLVQPGRSLRLSCTTSGFTFTDYYVSWVRQAPGKALEWVGF 
identity , about 66 % identity , about 67 % identity , about 68 % 
identity , about 69 % identity , about 70 % identity , about 71 % IRNKVNGYTTEFAASVRGRFTISRDNSKSILYLQMNSLKIEDTAVYYCAR 
identity , about 72 % identity , about 73 % identity , about 74 % 15 VSYYGRGWYFDYWGOGTTVTVSS identity , about 75 % identity , about 76 % identity , about 77 % 
identity , about 78 % identity , about 79 % identity , about 80 % 
identity , about 81 % identity , about 82 % identity , about 83 % ( SEQ ID NO : 17 ) 
identity , about 84 % identity , about 85 % identity , about 86 % EVOVVESGGGLVQPGGSLRLSCTTSGFTFTDYYVSWVRQFPGKALEWLGF 
identity , about 87 % identity , about 88 % identity , about 89 % 20 
IRNKVNGYTTEFSSSVKGRFTISRDNSKSTLYLQMNTLRVDDTAVYYCAR identity , or about 90 % identity to the entire variable region , 
the complementarity determining regions , or the framework VSYYGRGWYFDYWGQGTTLTVSS 
region sequence of SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID 
NO : 3 , SEQ ID NO : 4 , SEQ ID NO : 5 , or SEQ ID NO : 6 . 25 ( SEQ ID NO : 18 ) In other embodiments , the humanized 1B7 antibody com EVOVVESGGGLVOPGRSLRLSCTTSGFTFTDYYVSWVRQAPGKALEWLGF prises an immunoglobulin light chain variable region com 
prising an amino acid sequence having at least about 50 % 
identity , about 51 % identity , about 52 % identity , about 53 % 
identity , about 54 % identity , about 55 % identity , about 56 % 30 VSYYGRGWYFDYWGQGTTLTVSS 
identity , about 57 % identity , about 58 % identity , about 59 % 
identity , about 60 % identity , about 61 % identity , about 62 % 62 % The immunoglobulin light chain variable region com 
identity , about 63 % identity , about 64 % identity , about 65 % prises an amino acid sequence selected from : 
identity , about 66 % identity , about 67 % identity , about 68 % 
identity , about 69 % identity , about 70 % identity , about 71 % 35 11E6 : 
identity , about 72 % identity , about 73 % identity , about 74 % ( SEQ ID NO : 19 ) 
identity , about 75 % identity , about 76 % identity , about 77 % DIVMTOSTSSLSASLGDRVTISCRASQDIDNYLSWFQQKPDGTVKLLIYY 
identity , about 78 % identity , about 79 % identity , about 80 % TSRLHSGVPSRFSGSGSGTDYSLTISSLDQEDIATYFCQQGNTFPWTFGG identity , about 81 % identity , about 82 % identity , about 83 % 
identity , about 84 % identity , about 85 % identity , about 86 % 40 GTKLEIK 
identity , about 87 % identity , about 88 % identity , about 89 % cdr11E6 : identity , or about 90 % identity to the entire variable region , 
the complementarity determining regions , or the framework DIVMTQSPSSLSASVGDRVTISCRASQDIDNYLSWFOQKPGGTVKLLIYY 
region sequence of SEQ ID NO : 7 , SEQ ID NO : 8 , SEQ ID 45 TSRLHSGVPSRFSGSGSGTDYTLTISSLOPEDIATYFCQQGNTFPWTFGG NO : 9 , SEQ ID NO : 10 , SEQ ID NO : 11 , or SEQ ID NO : 12 . 
In one aspect , the present invention is directed to a GTKVEIK 
humanized 11E6 antibody that binds a pertussis toxin pro 
tein , and comprises an immunoglobulin heavy chain vari ( SEO ID NO : 21 ) 
0 DIVMTOSPSSLSASVGDRVTITCRASODIDNYLSWFOOKPGGTVKLLIYY 
region . The immunoglobulin heavy chain variable region 
comprises an amino acid sequence selected from : TSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYFCQQGNTFPWTFGG 
GTKVEIK 
IRNKVNGYTTEFSSSVKGRFTISRDNSKSILYLOMNSLKIEDTAVYYCAR 
( SEO ID NO : 20 ) 
abb11E6 : 
11E6 : 
( SEQ ID NO : 13 ) 
EVKVVESGGGLVOPGGSLRLSCTTSGFTFTDYYVSWVROFPGKALEWLGF 
55 sdr11E6 : 





( SEO ID NO : 14 ) 
EVQVVESGGGLVQPGRSLRLSCTTSGFTFTDYYVSWVRQAPGKALEWLGF 
fra1156 : 
( SEO ID NO : 23 ) 
DIVMTQSPSSLSASVGDRVTISCRASQDIDNYLSWFQQKPGGTVKLLIYY 
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- continued 65 % identity , about 66 % identity , about 67 % identity , about 
68 % identity , about 69 % identity , about 70 % identity , about 
71 % identity , about 72 % identity , about 73 % identity , about ( SEO ID NO : 24 ) 74 % identity , about 75 % identity , about 76 % identity , about 
5 77 % identity , about 78 % identity , about 79 % identity , about 
TSRLHSGVPSRFSGSGSGTDYTLTISSLOPEDIATYFCOOGNTFPWTFGG 80 % identity , about 81 % identity , about 82 % identity , about 
83 % identity , about 84 % identity , about 85 % identity , about GTKLEIK 86 % identity , about 87 % identity , about 88 % identity , about 
Any one of the disclosed 11E6 heavy chains can be paired 89 % identity , or about 90 % identity to the entire variable 
with any of the disclosed 11E6 light chains . By way of 10 region , the complementarity determining regions , or the 
illustration , the following pairs can be incorporated into an framework region sequence of SEQ ID NO : 13 , SEQ ID 
antibody of the present compositions and methods : SEQ ID NO : 14 , SEQ ID NO : 15 , SEQ ID NO : 16 , SEQ ID NO : 17 , 
NO : 13 / SEQ ID NO : 19 ; SEQ ID NO : 13 / SEQ ID NO : 20 ; and SEQ ID NO : 18 . 
SEO ID NO : 13 / SEO ID NO : 21 ; SEO ID NO : 13 / SEO ID In other embodiments , the humanized 11E6 antibody 
NO : 22 ; SEQ ID NO : 13 / SEQ ID NO : 23 ; SEQ ID NO : 15 comprises an immunoglobulin light chain variable region 
13 / SEQ ID NO : 24 ; SEQ ID NO : 14 / SEQ ID NO : 19 ; SEQ comprising an amino acid sequence having at least about 50 % identity , about 51 % identity , about 52 % identity , about ID NO : 14 / SEQ ID NO : 20 ; SEQ ID NO : 14 / SEQ ID NO : 53 % identity , about 54 % identity , about 55 % identity , about 21 ; SEQ ID NO : 14 / SEQ ID NO : 22 ; SEQ ID NO : 14 / SEQ 56 % identity , about 57 % identity , about 58 % identity , about 
ID NO : 23 ; SEQ ID NO : 14 / SEQ ID NO : 24 ; SEQ ID NO : 20 59 % identity , about 60 % identity , about 61 % identity , about 
15 / SEQ ID NO : 19 ; SEQ ID NO : 15 / SEQ ID NO : 20 ; SEQ 62 % identity , about 63 % identity , about 64 % identity , about 
ID NO : 15 / SEQ ID NO : 21 ; SEQ ID NO : 15 / SEQ ID NO : 65 % identity , about 66 % identity , about 67 % identity , about 
22 ; SEO ID NO : 15 / SEQ ID NO : 23 ; SEQ ID NO : 15 / SEQ 68 % identity , about 69 % identity , about 70 % identity , about 
ID NO : 24 ; SEQ ID NO : 16 / SEQ ID NO : 19 ; SEQ ID NO : 71 % identity , about 72 % identity , about 73 % identity , about 
16 / SEQ ID NO : 20 ; SEQ ID NO : 16 / SEQ ID NO : 21 ; SEQ 25 74 % identity , about 75 % identity , about 76 % identity , about 
ID NO : 16 / SEQ ID NO : 22 ; SEQ ID NO : 16 / SEQ ID NO : 77 % identity , about 78 % identity , about 79 % identity , about 
23 ; SEQ ID NO : 16 / SEQ ID NO : 24 ; SEQ ID NO : 17 / SEQ 80 % identity , about 81 % identity , about 82 % identity , about 
ID NO : 19 ; SEO ID NO : 17 / SEO ID NO : 20 ; SEQ ID NO : 83 % identity , about 84 % identity , about 85 % identity , about 
17 / SEQ ID NO : 21 ; SEQ ID NO : 17 / SEQ ID NO : 22 ; SEQ 86 % identity , about 87 % identity , about 88 % identity , about 
ID NO : 17 / SEQ ID NO : 23 ; SEQ ID NO : 17 / SEQ ID NO : 30 89 % identity , or about 90 % identity to the entire variable 
24 ; SEQ ID NO : 18 / SEQ ID NO : 19 ; SEQ ID NO : 18 / SEQ region , the complementarity determining regions , or the 
ID NO : 20 ; SEQ ID NO : 18 / SEQ ID NO : 21 ; SEQ ID NO : framework region sequence of SEQ ID NO : 19 , SEQ ID 
18 / SEQ ID NO : 22 ; SEQ ID NO : 18 / SEQ ID NO : 23 ; and NO : 20 , SEQ ID NO : 21 , SEQ ID NO : 22 , SEQ ID NO : 23 , 
SEO ID NO : 18 / SEO ID NO : 24 . and SEO ID NO : 24 . 
In one embodiment , the humanized 11E6 antibody com - 35 Homology or identity may be determined in various ways 
prises an immunoglobulin heavy chain variable region com - that are within the skill in the art , for instance , using publicly 
prising the amino acid sequence of SEQ ID NO : 14 , and an available computer software such as BLAST , BLAST - 2 , 
immunoglobulin light chain variable region comprising the ALIGN or Megalign ( DNASTAR ) software . BLAST ( Basic 
amino acid sequence of SEQ ID NO : 20 . Local Alignment Search Tool ) analysis using the algorithm 
In one embodiment , the humanized 11E6 antibody com - 40 employed by the programs blastp , blastn , blastx , tblastn and 
prises an immunoglobulin heavy chain variable region com - tblastx ( Karlin et al . , ( 1990 ) PROC . NATL . ACAD . Sci . USA 87 , 
prising the amino acid sequence of SEQ ID NO : 15 , and an 2264 - 2268 ; Altschul , ( 1993 ) J . Mol . Evol . 36 , 290 - 300 ; 
immunoglobulin light chain variable region comprising the Altschul et al . , ( 1997 ) NUCLEIC ACIDS Res . 25 , 3389 - 3402 , 
amino acid sequence of SEQ ID NO : 21 . incorporated by reference ) are tailored for sequence simi 
In one embodiment , the humanized 11E6 antibody com - 45 larity searching . The approach used by the BLAST program 
prises an immunoglobulin heavy chain variable region com - is to first consider similar segments between a query 
prising the amino acid sequence of SEQ ID NO : 16 , and an sequence and a database sequence , then to evaluate the 
immunoglobulin light chain variable region comprising the statistical significance of all matches that are identified and 
amino acid sequence of SEQ ID NO : 22 . finally to summarize only those matches which satisfy a 
In one embodiment , the humanized 11E6 antibody com - 50 preselected threshold of significance . For a discussion of 
prises an immunoglobulin heavy chain variable region com - basic issues in similarity searching of sequence databases 
prising the amino acid sequence of SEQ ID NO : 17 , and an see Altschul et al . , ( 1994 ) NATURE GENETICS 6 , 119 - 129 which 
immunoglobulin light chain variable region comprising the is fully incorporated by reference . Those skilled in the art 
amino acid sequence of SEQ ID NO : 23 . can determine appropriate parameters for measuring align 
In one embodiment , the humanized 11E6 antibody com - 55 ment , including any algorithms needed to achieve maximal 
prises an immunoglobulin heavy chain variable region com alignment over the full length of the sequences being 
prising the amino acid sequence of SEQ ID NO : 18 , and an compared . The search parameters for histogram , descrip 
immunoglobulin light chain variable region comprising the tions , alignments , expect ( i . e . , the statistical significance 
amino acid sequence of SEQ ID NO : 24 . threshold for reporting matches against database sequences ) , 
In other embodiments , the humanized 11E6 antibody 60 cutoff , matrix and filter are at the default settings . The 
comprises an immunoglobulin heavy chain variable region default scoring matrix used by blastp , blastx , tblastn , and 
comprising an amino acid sequence having at least about tblastx is the BLOSUM62 matrix ( Henikoff et al . , ( 1992 ) 
50 % identity , about 51 % identity , about 52 % identity , about PROC . NATL . ACAD . SCI . USA 89 , 10915 - 10919 , fully incor 
53 % identity , about 54 % identity , about 55 % identity , about porated by reference ) . Four blastn parameters may be 
56 % identity , about 57 % identity , about 58 % identity , about 65 adjusted as follows : Q = 10 ( gap creation penalty ) ; R = 10 ( gap 
59 % identity , about 60 % identity , about 61 % identity , about extension penalty ) ; wink = 1 ( generates word hits at every 
62 % identity , about 63 % identity , about 64 % identity , about wink . sup . th position along the query ) ; and gapw = 16 ( sets 
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the window width within which gapped alignments are hydrophobic amino acid residue which may include a hydro 
generated ) . The equivalent Blastp parameter settings may be phobic , aliphatic amino acid selected from glycine ( G ) , 
Q = 9 ; R = 2 ; wink = 1 ; and gapw = 32 . Searches may also be alanine ( A ) , leucine ( L ) , isoleucine ( I ) , methionine ( M ) , or 
conducted using the NCBI ( National Center for Biotechnol valine ( V ) or a hydrophobic , aromatic amino acid selected 
ogy Information ) BLAST Advanced Option parameter ( e . g . : 5 from phenylalanine ( F ) , tryptophan ( W ) , or tyrosine ( Y ) . 
- G , Cost to open gap [ Integer ] : default = 5 for nucleotides / 11 The ability of an antibody to bind a specific epitope can 
for proteins ; - E , Cost to extend gap [ Integer ) : default = 2 for be described by the equilibrium dissociation constant ( K ) ) . 
nucleotides / 1 for proteins ; - q , Penalty for nucleotide mis - In certain embodiments , the present invention provides a 
match [ Integer ) : default = - 3 ; - r , reward for nucleotide match humanized 1B7 antibody that binds the pertussis toxin 
[ Integer ) : default = 1 ; - e , expect value [ Real ] : default = 10 ; 10 protein with a K , of about 20 nM or lower , or about 15 nM 
- W , wordsize [ Integer ) : default = 11 for nucleotides / 28 for or lower , or about 10 nM or lower , or about 5 nM or lower . 
megablast / 3 for proteins ; - y , Dropoff ( X ) for blast exten - In an embodiment , the humanized 1B7 antibody binds the 
sions in bits : default = 20 for blastn / 7 for others ; - X , X pertussis toxin protein with a Ky of about 5 nM or lower or 
dropoff value for gapped alignment ( in bits ) : default = 15 for about 3 nM or lower . In illustrative embodiments , the 
all programs , not applicable to blastn ; and - Z , final X 15 humanized 1B7 antibody binds the pertussis toxin protein 
dropoff value for gapped alignment ( in bits ) : 50 for blastn , with a K , of about 5 nM , about 4 . 5 nM , about 4 nM , about 
25 for others ) . ClustalW for pairwise protein alignments 3 . 5 nM , about 3 nM , about 2 . 5 nM , about 2 nM , about 1 . 5 
may also be used ( default parameters may include , e . g . , nM , about 1 nM , or about 0 . 5 nM . 
Blosum 62 matrix and Gap Opening Penalty = 10 and Gap In certain embodiments , the present invention provides a 
Extension Penalty = 0 . 1 ) . A Bestfit comparison between 20 humanized 11E6 antibody that binds the pertussis toxin 
sequences , available in the GCG package version 10 . 0 , uses protein with a K , of about 20 , about 19 , or about 18 , or 
DNA parameters GAP = 50 ( gap creation penalty ) and about 17 , or about 16 , or about 15 nM or lower . In an 
LEN = 3 ( gap extension penalty ) and the equivalent settings embodiment , the humanized 11E6 antibody binds the per 
in protein comparisons are GAP = 8 and LEN = 2 . tussis toxin protein with a K , of 12 nM or lower . In 
In each of the foregoing embodiments , it is contemplated 25 illustrative embodiments , the humanized 1B7 antibody 
herein that the immunoglobulin heavy chain variable region binds the pertussis toxin protein with a Ky of about 15 nM , 
sequences and / or light chain variable region sequences may about 14 . 5 nM , about 14 nM , about 13 . 5 nM , about 13 nM , 
contain amino acid alterations ( e . g . , amino acid substitu - about 12 . 5 nM , about 12 nM , about 11 . 5 nM , about 11 nM , 
tions , deletions , or insertions ) relative to SEQ ID NOs : 1 - 24 . about 10 . 5 nM , about 10 nM , about 9 . 5 nM , about 9 nM , 
For example , the immunoglobulin heavy chain variable 30 about 8 . 5 nM , about 8 nM , about 7 . 5 nM , about 7 nM , about 
region sequences and / or light chain variable region 6 . 5 nM , about 6 nM , about 5 . 5 nM , about 5 nM , about 4 . 5 
sequences may contain from about 1 to about 50 mutations , nM , about 4 nM , about 3 . 5 nM , about 3 nM , about 2 . 5 nM , 
from about 1 to about 40 mutations , from about 1 to about about 2 nM , about 1 . 5 nM , about 1 nM , or about 0 . 5 nM . 
35 mutations , from about 1 to about 30 mutations , about 1 In some embodiments , the humanized antibodies 
to about 25 mutations , from about 1 to about 20 mutations , 35 described herein compete with an antibody that is capable of 
about 1 to about 15 mutations , or from about 1 to about 10 binding a pertussis toxin protein . Where the humanized 
mutations independently selected from substitutions , dele - antibody competes with an antibody ( competitor antibody ) 
tions , or insertions with respect to SEQ ID NOs : 1 - 24 . In for binding a pertussis toxin protein , the humanized anti 
various embodiments , the immunoglobulin heavy chain bodies of the invention inhibit ( completely or partially ) 
variable region sequences and / or light chain variable region 40 binding of the competitor antibody to a measurable extent . 
sequences have about 1 mutation , about 2 mutations , about The inhibition of binding may be measured by any of the 
3 mutations , about 4 mutations , about 5 mutations , about 6 methods known in the art . In general , a humanized antibody 
mutations , about 7 mutations , about 8 mutations , about 9 is considered to competitively inhibit binding of a competi 
mutations , about 10 mutations , about 11 mutations , about 12 tor antibody ( e . g . , mouse 1B7 or 11E6 antibody as described 
mutations , about 13 mutations , about 14 mutations , about 15 45 by Sato et al . , ( 1990 ) , Infection and Immunity , 58 ( 10 ) : 
mutations , about 16 mutations , about 17 mutations , about 18 3369 - 3374 or humanized 1B7 antibody as described by 
mutations , about 19 mutations , about 20 mutations , about 21 Maynard et al . , U . S . Pat . No . 8 , 653 , 243 , which are herein 
mutations , about 22 mutations , about 23 mutations , about 24 incorporated by reference in their entireties ) , if binding of 
mutations , about 25 mutations , about 26 mutations , about 27 the competitor antibody to the antigen is reduced by at least 
mutations , about 28 mutations , about 29 mutations , about 30 50 about 10 % , at least about 20 % , at least about 30 % , at least 
mutations , about 31 mutations , about 32 mutations , about 33 about 40 % , at least about 50 % , at least about 60 % , at least 
mutations , about 34 mutations , about 35 mutations , about 36 about 70 % , at least about 80 % , or at least about 90 % , in the 
mutations , about 37 mutations , about 38 mutations , about 39 presence of the humanized antibody . Thus , in some embodi 
mutations , about 40 mutations , about 41 mutations , about 42 ments , the antibody provided herein binds to a pertussis 
mutations , about 43 mutations , about 44 mutations , about 45 55 toxin protein competitively with a mouse 1B7 or 11E6 
mutations , about 46 mutations , about 47 mutations , about 48 antibody as described by Sato et al . , ( 1990 ) , Infection and 
mutations , about 49 mutations , or about 50 mutations , Immunity , 58 ( 10 ) : 3369 - 3374 . In other embodiments , the 
relative to SEQ ID NOs : 1 - 24 . Illustrative amino acids that antibody provided herein inhibits ( completely or partially ) 
may be incorporated include a hydrophilic amino acid the binding of a mouse 1B7 or 11E6 antibody . In some 
residue , which may include a polar and positively charged 60 further embodiments , the antibody provided herein 
hydrophilic residue selected from arginine ( R ) and lysine decreases the binding of a mouse 1B7 or 11E6 antibody in 
( K ) , a polar and neutral of charge hydrophilic residue a competition assay by about 10 % , about 20 % , about 30 % , 
selected from asparagine ( N ) , glutamine ( Q ) , serine ( S ) , about 40 % , about 50 % , about 60 % , about 70 % , about 80 % , 
threonine ( T ) , proline ( P ) , and cysteine ( C ) , a polar and about 90 % or about 100 % . 
negatively charged hydrophilic residue selected from aspar - 65 Although the embodiments illustrated in the Examples 
tate ( D ) and glutamate ( E ) , or an aromatic , polar and may comprise pairs of variable regions , pairs of full length 
positively charged hydrophilic including histidine ( H ) ; a antibody chains , or pairs of CDR1 , CDR2 and CDR3 
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regions , one from a heavy chain and one from a light chain , one expression vector ( e . g . , one expression vector express 
a skilled artisan will recognize that alternative embodiments ing a polypeptide comprising an entire , or part of , a heavy 
may comprise single heavy chain variable regions or single chain or heavy chain variable region , and another expression 
light chain variable regions , single full length antibody vector expressing a polypeptide comprising an entire , or part 
chains , or CDR1 , CDR2 and CDR3 regions from one 5 of , a light chain or light chain variable region ) . 
antibody chain , either heavy or light . A polypeptide comprising an immunoglobulin heavy 
Production of Antibodies chain variable region or light chain variable region can be 
Methods for producing antibodies of the invention are produced by growing a host cell transfected with an expres described herein . For example , DNA molecules encoding sion vector encoding such variable region , under conditions light chain variable regions and / or heavy chain variable 10 that permit expression of the polypeptide . Following expres regions can be chemically synthesized using the sequence sion , the polypeptide can be harvested and purified using information provided herein . Synthetic DNA molecules can techniques well known in the art , e . g . , affinity tags such as be ligated to other appropriate nucleotide sequences , includ glutathione - S - transferase ( GST ) and histidine tags or by ing , e . g . , constant region coding sequences , and expression 
control sequences , to produce gene expression constructs 15 Chromatography by way or non - limiting example , based on constructs 15 chromatography ( by way of non - limiting example , based on 
encoding the desired antibodies . Alternatively , the size , charge , and / or specific binding ) . 
sequences provided herein can be cloned out of hybridomas A monoclonal antibody that binds the pertussis toxin 
by hybridization techniques or polymerase chain reaction protein , or an antigen - binding fragment of the antibody , can 
( PCR ) techniques using synthetic nucleic acid probes . be produced by growing a host cell transfected , transformed 
Nucleic acids encoding desired antibodies can be incor - 20 or transduced with : ( a ) an expression vector that encodes a 
porated ( ligated ) into expression vectors , which can be complete or partial immunoglobulin heavy chain , and a 
introduced into host cells through transfection , transforma separate expression vector that encodes a complete or partial 
tion , or transduction techniques . For example , nucleic acids immunoglobulin light chain ; or ( b ) a single expression 
encoding desired antibodies can be introduced into host cells vector that encodes both chains ( e . g . , complete or partial 
by retroviral transduction . Illustrative host cells are E . coli 25 heavy and light chains ) , under conditions that permit expres 
cells , Chinese hamster ovary ( CHO ) cells , human embryonic sion of both chains . The intact antibody ( or antigen - binding 
kidney 293 ( HEK 293 ) cells , HeLa cells , baby hamster fragment ) can be harvested and purified using techniques 
kidney ( BHK ) cells , monkey kidney cells ( COS ) , human well known in the art , e . g . , Protein A , Protein G , affinity tags 
hepatocellular carcinoma cells ( e . g . , Hep G2 ) , and myeloma such as glutathione - S - transferase ( GST ) and histidine tags or 
cells that do not otherwise produce IgG protein . Trans - 30 by chromatography . It is within ordinary skill in the art to 
formed host cells can be grown under conditions that permit express the heavy chain and the light chain from a single 
the host cells to express the genes that encode the immu - expression vector or from two separate expression vectors . 
noglobulin light and / or heavy chain variable regions . Antibody Modifications 
Specific expression and purification conditions will vary There are standard methods for reducing or eliminating 
depending upon the expression system employed . For 35 the antigenicity of antibodies and antibody fragments that 
example , if a gene is to be expressed in E . coli , it is first are known in the art . When the antibodies are to be admin 
cloned into an expression vector by positioning the engi istered to a human , the antibodies preferably are “ human 
neered gene downstream from a suitable bacterial promoter , ized ” to reduce or eliminate antigenicity in humans . It is 
e . g . , Trp or Tac , and a prokaryotic signal sequence . The contemplated that the humanized antibodies have at least the 
expressed secreted protein accumulates in refractile or inclu - 40 same or substantially the same affinity for the antigen as the 
sion bodies , and can be harvested after disruption of the cells non - humanized mouse antibody from which it was derived . 
by French press or sonication . The refractile bodies then are However , it is noted that while humanization approaches 
solubilized , and the proteins refolded and cleaved by meth - are known in the art , such humanization approaches are 
ods known in the art . often hindered by reductions in affinity ( e . g . relative to the 
If the engineered gene is to be expressed in eukaryotic 45 original murine antibody ) . This may be , without wishing to 
host cells , e . g . , CHO cells , it is first inserted into an be bound by theory , due to the fact that the CDRs are not 
expression vector containing a suitable eukaryotic promoter , maintained workable configuration by the human frame 
a secretion signal , IgG enhancers , and various introns . This works . In this case , a small number of changes to the human 
expression vector optionally contains sequences encoding framework sequences are made . These individual amino 
all or part of a constant region , enabling an entire , or a part 50 acid changes improve the affinity without making significant 
of , a heavy or light chain to be expressed . The gene construct deviations from the human antibody structure so that the 
can be introduced into eukaryotic host cells using transfec antibodies continue to resemble human antibodies . In that 
tion , transformation , or transduction techniques . The host way , the antibodies can be used as for therapeutic purposes 
cells express V , or Vh fragments , V2 - Vh heterodimers , in humans without inducing an immune response . The 
V - V , or V - Vh single chain polypeptides , complete heavy 55 choice of amino acids to change and the specific changes to 
or light immunoglobulin chains , or portions thereof , each of be made are part of the present invention . 
which may be attached to a moiety having another function . In one humanization approach , chimeric proteins are 
In some embodiments , a host cell is transfected with a single created in which mouse immunoglobulin constant regions 
vector expressing a polypeptide expressing an entire , or part are replaced with human immunoglobulin constant regions . 
of , a heavy chain ( e . g . , a heavy chain variable region ) or a 60 See , e . g . , Morrison et al . , 1984 , PROC . NAT . ACAD . SCI . 
light chain ( e . g . , a light chain variable region ) . In other 81 : 6851 - 6855 , Neuberger et al . , 1984 , NATURE 312 : 604 - 608 ; 
embodiments , a host cell is transfected with a single vector U . S . Pat . No . 6 , 893 , 625 ( Robinson ) ; U . S . Pat . No . 5 , 500 . 362 
encoding ( a ) a polypeptide comprising a heavy chain vari ( Robinson ) ; and U . S . Pat . No . 4 , 816 , 567 ( Cabilly ) . For 
able region and a polypeptide comprising a light chain example , in some embodiments , any one of SEQ ID NO : 1 , 
variable region , or ( b ) an entire immunoglobulin heavy 65 or SEQ ID NO : 7 , or SEQ ID NO : 13 , or SEQ ID NO : 19 
chain and an entire immunoglobulin light chain . In still other can be the variable regions that are paired with a human 
embodiments , a host cell is co - transfected with more than constant region . 
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In an approach known as CDR grafting , the CDRs of the Methods of Using Antibodies 
light and heavy chain variable regions are grafted into In one aspect , the method of the invention involves 
frameworks from another species . For example , murine treating a patient with Bordetella pertussis , comprising 
CDRs and non - CDR residues involved in antigen binding administering to the patient the humanized 1B7 antibody 
can be grafted into human sequences . Residues involved in 5 ( e . g . in an effective amount ) and / or the humanized 11E6 
maintaining the combining site structure and residues antibody ( e . g . in an effective amount ) , or pharmaceutical 
involved in maintaining V , : Vy contact may also be grafted . compositions including the antibody or antibodies . 
CDR grafting is described in U . S . Pat . No . 7 , 022 , 500 In another aspect , the method of the invention involves a 
( Queen ) ; U . S . Pat . No . 6 , 982 , 321 ( Winter ) ; U . S . Pat . No . method of preventing a Bordetella pertussis infection , com 
6 , 180 , 370 ( Queen ) ; U . S . Pat . No . 6 , 054 , 297 ( Carter ) ; U . S . 10 prising administering to a patient the humanized 1B7 anti 
Pat . No . 5 , 693 , 762 ( Queen ) ; U . S . Pat . No . 5 , 859 , 205 body ( e . g . in an effective amount ) and / or the humanized 
( Adair ) ; U . S . Pat . No . 5 , 693 , 761 ( Queen ) ; U . S . Pat . No . 11E6 antibody ( e . g . in an effective amount ) , or pharmaceu 
5 , 565 , 332 ( Hoogenboom ) ; U . S . Pat . No . 5 , 585 , 089 ( Queen ) ; tical compositions including the antibody or antibodies and , 
U . S . Pat . No . 5 , 530 , 101 ( Queen ) ; Jones et al . ( 1986 ) in some embodiments , the patient is at risk for a Bordetella 
NATURE 321 : 522 - 525 ; Riechmann et al . ( 1988 ) NATURE 15 pertussis infection ( e . g . the patient is a pre - vaccination 
332 : 323 - 327 ; Verhoeyen et al . ( 1988 ) SCIENCE 239 : infant and / or the patient has been exposed to a pertussis 
1534 - 1536 ; and Winter ( 1998 ) FEBS LETT 430 : 92 - 94 . toxin ) . 
In an approach called grafting of abbreviated CDRs , Leukocytosis or elevation in white blood cell count is 
abbreviated CDRs , as defined by Padlan et al . , ( 1995 ) characteristic of Bordetella pertussis infections . In one 
FASEB J 9 : 133 - 139 , and non - CDR residues involved in 20 embodiment , the method of the invention comprises a reduc 
antigen binding , are transplanted into a human sequence . tion in white blood cell count in the patient . In an embodi 
Residues involved in maintaining the combining site struc ment , the method of the invention results in an acceleration 
ture and residues involved in maintaining V , : Vy contact of the resolution of leukocytosis . In another embodiment , 
may also be grafted . the method of the invention results in a reduction of the 
Other methods to reduce immunogenicity include “ SDR - 25 maximum white blood cell count during the course of the 
transfer , " " veneering , ” and “ Frankensteining . ” See , e . g . , infection . 
Padlan et al . , ( 1995 ) FASEB J 9 : 133 - 139 , Wu et al . , ( 1992 ) In various embodiments , the method of the invention 
MOL IMMUNOL 29 : 1141 - 1146 , and Padlan et al . , ( 1991 ) MOL results in an improvement of whooping cough in the patient . 
IMMUNOL 28 : 489 - 498 . In the SDR - transfer approach , residues In one embodiment , the coughing symptoms of the patient 
involved in antigen binding ( i . e . , the specificity - determining 30 are improved . For example , the method reduces the fre 
residues or SDRs ) are transplanted into a human sequence . quency of coughing or the number of coughs ( or coughing 
Residues involved in maintaining the combining site struc - episodes ) in the patient . In various embodiments , the method 
ture and residues involved in maintaining V , : Vy contact reduces the number of coughs or coughing episodes by at 
may also be transplanted . In the veneering approach , the least about 1 per hour , at least about 2 per hour , at least about 
surface accessible amino acid residues in the murine anti - 35 3 per hour , at least about 4 per hour , at least about 5 per hour , 
body are replaced by amino acid residues more frequently at least about 6 per hour , at least about 7 per hour , at least 
found at the same positions in a human antibody . For about 8 per hour , at least about 9 per hour , at least about 10 
example , the framework residues , which are exposed to per hour , at least about 15 per hour , at least about 20 per 
solvent , are replaced with their homologues from a human hour , at least about 25 per hour , at least about 30 per hour , 
sequence . The CDRs and non - CDR residues involved in 40 at least about 35 per hour , at least about 40 per hour , at least 
antigen binding are preserved . In the Frankensteining about 45 per hour , at least about 50 per hour , at least about 
approach , the CDRs are transplanted into a composite 55 per hour , at least about 60 per hour , at least about 65 per 
sequence constructed from the most similar human frame - hour , at least about 70 per hour , at least about 75 per hour , 
work regions . Residues involved in maintaining the com at least about 80 per hour , at least about 85 per hour , at least 
bining site structure and residues involved in maintaining 45 about 90 per hour , at least about 95 per hour , or at least about 
Vz : Vh contact may also be transplanted . 100 per hour . In another example , the method reduces the 
Any suitable approach , including any of the above duration of coughing in the patient . For example , the method 
approaches , can be used to reduce or eliminate human reduces the duration of coughing during the course of the 
immunogenicity of an antibody . infection by at least about three months , about two months , 
In addition , it is possible to create fully human antibodies 50 about one month , about 4 weeks , about 3 weeks , about 2 
in mice . Fully human mAbs lacking any non - human weeks , about 1 week , about 5 days , about 4 days , about 3 
sequences can be prepared from human immunoglobulin days , about 2 days , or about 1 day . In a further embodiment , 
transgenic mice by techniques referenced in , e . g . , Lonberg et the number of whoops is reduced in the patient . 
al . , NATURE 368 : 856 - 859 , 1994 ; Fishwild et al . , NATURE In another embodiment , the method of the invention 
BIOTECHNOLOGY 14 : 845 - 851 , 1996 ; and Mendez et al . , NATURE 55 reduces the level of the Bordetella pertussis bacteria in the 
GENETICS 15 : 146 - 156 , 1997 . Human mAbs can also be pre nasopharynx of the patient . In a further embodiment , the 
pared and optimized from phage display libraries by tech method of the invention reduces the level of the Bordetella 
niques referenced in , e . g . , Knappik et al . , J . Mol . BIOL . pertussis bacteria in the lung of the patient ( e . g . bacterial 
296 : 57 - 86 , 2000 ; and Krebs et al . , J . Immunol . Meth . lung colonization ) . For example , the method reduces the 
254 : 67 - 84 2001 ) . 60 Bordetella pertussis levels in the nasopharynx and / or the 
If the antibody is for use as a therapeutic , it can be lungs by about 95 % , about 90 % , about 80 % , about 70 % , 
conjugated to an effector agent such as a small molecule or about 60 % , about 50 % , about 40 % , about 30 % , about 20 % , 
a radionuclide using standard in vitro conjugation chemis - about 10 % , or about 5 % . 
tries . If the effector agent is a polypeptide , the antibody can In one embodiment , the method of the invention results in 
be chemically conjugated to the effector or joined to the 65 neutralization ( inhibition or antagonization ) of the pertussis 
effector as a fusion protein . Construction of fusion proteins toxin protein . For example , antibodies of the invention can 
is within ordinary skill in the art . bind to the pertussis toxin protein so as to partially or 
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completely inhibit one or more biological activities of the remain at the same level for 2 to 3 weeks , and then gradually 
pertussis toxin protein . Among the biological activities of a decrease . The paroxysmal stage usually lasts 1 to 6 weeks 
pertussis toxin protein that a neutralizing antibody may but may persist for up to 10 weeks . In various embodiments , 
inhibit or block is the ability of a pertussis toxin protein to the present compositions and methods reduce the length of 
bind cellular receptors . The receptor binding region of a 5 this stage . In the convalescent stage , recovery is gradual . 
pertussis toxin protein consists of four polypeptide subunits The cough becomes less paroxysmal and disappears in 2 to 
referred to as subunit S2 , subunit S3 , subunit S4 and subunit 3 weeks . In various embodiments , the present compositions 
S5 , respectively . Examples of cellular receptors that are and methods accelerate the onset of this stage and / or reduce 
bound by the subunits S2 , S3 , S4 , and S5 of a pertussis toxin its duration . Further , in various embodiments , the present 
protein are members of the N - linked sialoglycoprotein fam - 10 compositions and methods prevent or reduce the recurrence 
ily such as fetuin , haptoblobin , and transferrin . In an illus of paroxysms , which may occur with subsequent respiratory 
trative embodiment , the humanized antibodies of the inven - infections . In various embodiments , the present composi 
tion prevent the pertussis toxin protein from binding to its tions and methods prevent or reduce one or more of the onset 
cellular receptor . In another embodiment , the humanized of secondary bacterial pneumonia , neurologic complications 
antibodies of the invention alter the intracelluar trafficking 15 such as seizures and encephal - opathy , hypoxia , otitis media , 
steps of the pertussis toxin such that the toxin does not reach dehydration , pneumothorax , epistaxis , subdural hematomas , 
the cellular cytosol . Another important activity of a pertussis hernias , rectal prolapsed , difficulty sleeping , urinary incon 
toxin protein that may be inhibited by antibodies of the tinence , pneumonia , and rib fracture . Further , in some 
invention is the enzymatic activity of the pertussis toxin embodiments , the present compositions and methods reduce 
protein as ADP ribosylase towards G proteins . The subunit 20 or prevent necrotizing bronchiolitis , pneumonia ( e . g . from 
conferring to the enzymatic activity as ADP - ribosylase in a Bordetella pertussis ) , pulmonary edema , pulmonary hyper 
pertussis toxin protein is subunit S1 . In some embodiments , tension , and death . 
the pertussis toxin protein is a pertussis holotoxin . A per - In an embodiment , methods of the invention involve 
tussis holotoxin as referred to herein as a pertussis toxin co - administration of the humanized 1B7 antibody and the 
protein that includes all five pertussis toxin protein subunits . 25 humanized 11E6 antibody to the patient . In some embodi 
In other embodiments , the pertussis toxin protein is a ments , co - administration produces synergistic effects . Co 
truncated pertussis toxin protein . A truncated pertussis pro - administration of the humanized 1B7 antibody and the 
tein as referred to herein includes at least one of the pertussis humanized 11 E6 antibody may be simultaneous or sequen 
toxin protein subunits ( . e . , 51 , S2 , S3 , S4 and S5 ) . Pertussis tial . 
toxin proteins of various forms are described in , for 30 In some embodiments , the humanized 1B7 antibody and 
example , U . S . Pat . No . 8 , 653 , 243 , which is herein incorpo - the humanized 11E6 antibody are administered to a subject 
rated by reference in its entirety . simultaneously . The term " simultaneously ” as used herein , 
In various embodiments , the present compositions and means that the humanized 1B7 antibody and the humanized 
methods are useful in the treatment or prevention of any of 11E6 antibody are administered with a time separation of no 
the stages of pertussis infections . For example , the incuba - 35 more than about 60 minutes , such as no more than about 30 
tion period of pertussis is commonly 7 - 10 days , with a range minutes , no more than about 20 minutes , no more than about 
of 4 - 21 days , and rarely may be as long as 42 days . In 10 minutes , no more than about 5 minutes , or no more than 
various embodiments , the present compositions and meth - about 1 minute . Administration of the humanized 1B7 
ods increase the length of the incubation period by making antibody and the humanized 11E6 antibody can be by 
the infection more difficult to come about . The clinical 40 simultaneous administration of a single formulation ( e . g . , a 
course of the illness is divided into three stages . The first formulation comprising the humanized 1B7 antibody and 
stage , the catarrhal stage , is characterized by the insidious the humanized 11E6 antibody ) or of separate formulations 
onset of coryza , sneezing , low - grade fever , and a mild , ( e . g . , a first formulation including the humanized 1B7 anti 
occasional cough , similar to the common cold . The cough body and a second formulation including the humanized 
gradually becomes more severe , and after 1 - 2 weeks , the 45 11E6 antibody ) . 
second , or paroxysmal stage , begins . In various embodi - Co - administration does not require the therapeutic agents 
ments , the present compositions and methods , reduce the to be administered simultaneously , if the timing of their 
length of the catarrhal stage and , optionally , prevent it from administration is such that the pharmacological activities of 
advancing to the paroxysmal stage . In various embodiments , the humanized 1B7 antibody and the 11 E6 antibody overlap 
the present compositions and methods treat one or more of 50 in time , thereby exerting a combined therapeutic effect . For 
coryza , sneezing , low - grade fever , and cough . It is during example , the humanized 1B7 antibody and the humanized 
the paroxysmal stage that the diagnosis of pertussis is 11E6 antibody can be administered sequentially . The term 
usually suspected . Characteristically , a patient has bursts , or " sequentially ” as used herein means that the humanized 1B7 
paroxysms , of numerous , rapid coughs , apparently due to antibody and the humanized 11 E6 antibody are administered 
difficulty expelling thick mucus from the tracheobronchial 55 with a time separation of more than about 60 minutes . For 
tree . At the end of the paroxysm , a long inspiratory effort is example , the time between the sequential administration of 
usually accompanied by a characteristic high - pitched the humanized 1B7 antibody and the humanized 1156 
whoop . During such an attack , the patient may become antibody can be more than about 60 minutes , more than 
cyanotic . Children and young infants , especially , appear about 2 hours , more than about 5 hours , more than about 10 
very ill and distressed . Vomiting and exhaustion commonly 60 hours , more than about 1 day , more than about 2 days , more 
follow the episode . In various embodiments , the present than about 3 days , or more than about 1 week apart . The 
compositions and methods reduce the quantity and / or fre - optimal administration times will depend on the rates of 
quency of paroxysms . In various embodiments , the present metabolism , excretion , and / or the pharmacodynamic activ 
compositions and methods prevent a patient from becoming ity of the humanized 1B7 antibody and the humanized 11E6 
cyanotic . Paroxysmal attacks occur more frequently at night , 65 antibody being administered . 
with an average of 15 attacks per 24 hours . During the first For example , in some embodiments , the antibodies of the 
1 or 2 weeks of this stage , the attacks increase in frequency , present invention have a peak in a serum concentration ( e . g . 
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a beta half - life ) of at least about 30 , or about 35 , or about 40 , the time at which the humanized 1B7 antibody being admin 
or about 45 , or about 50 , or about 55 , or about 60 , or about istered has reached about 50 % , about 60 % , about 70 % , 
65 , or about 70 , or about 75 , or about 80 hours post about 80 % , about 90 % , or about 100 % of its pharmacody 
administration or at least about 1 day , about 2 days , about 3 namic activity . 
days , about 4 days , about 5 days , about 6 days , about 7 days , 5 Co - administration also does not require the therapeutic 
about 8 days , about 9 days , about 10 days , about 11 days , agents to be administered to the patient by the same route of 
about 12 days , about 13 days , about 14 days , about 15 days , administration . Rather , each therapeutic agent can be admin 
about 16 days , about 17 days , about 18 days , about 19 days , istered by any appropriate route , for example , parenterally or 
about 20 days , about 21 days , about 22 days , about 23 days , non - parenterally . In an embodiment , the therapeutic agents 
about 24 days , or about 25 days ) . In some embodiments , the 10 may be administered orally to the subject . In another 
antibodies of the present invention have prolonged half - embodiment , the therapeutic agents may be administered 
lives . In some embodiments , the antibodies of the present parenterally , including for example , intravenous , intramus 
invention have an in vivo half - life of about 200 , or about cular , intraperitoneal , subcutaneous and intra - articular injec 
225 , or about 250 , or about 275 , or about 300 hours or about tion and infusion , among others . In an embodiment , the 
7 days , about 8 days , about 9 days , about 10 days , about 11 15 therapeutic agents may be administered through intramus 
days , about 12 days , about 13 days , about 14 days , about 15 cular injection to the subject . 
days , about 16 days , about 17 days , about 18 days , about 19 In another embodiment , the method includes administer 
days , about 20 days , about 21 days , about 22 days , about 23 ing to a patient the humanized 1B7 antibody and / or the 11E6 
days , about 24 days , about 25 days , about 26 days , about 27 antibody , along with antimicrobial agents . It is contemplated 
days , about 28 days , about 29 days , about 30 days , about 31 20 that co - administration of the humanized 1B7 antibody and / 
days , about 32 days , about 33 days , about 34 days , or about or the 11E6 antibody along with antimicrobial agents pro 
35 days , e . g . about 1 or about 2 weeks , or about 3 weeks , duces synergistic effects . Illustrative antimicrobial agents 
about 4 weeks , or about 5 weeks ) . that may be used for the invention include , but are not 
Accordingly , in some embodiments , a patient may receive limited to azithromycin , clarithromycin , erythromycin , 
a first administration ( e . g . infusion or intramuscular ( IM ) 25 trimethoprim - sulfamethoxasole , roxithromycin , ketolides 
injection ) of the inventive antibodies as part of a treatment ( e . g . , telithromycin ) ampicillin , amoxicillin , tetracycline , 
method and may receive a further administration ( e . g . infu - chloramphenicol , fluoroquinolones ( e . g . , ciprofloxacin , 
sion or intramuscular injection ) after a peak in serum levofloxacin , ofloxacin , moxifloxacin ) , and cephalosporins . 
concentration and / or the in vivo half - life of the antibodies of In an embodiment , the antimicrobial agent is erythromycin . 
the present invention ( e . g . the dose of the further adminis - 30 In various embodiments , the method of the invention 
tration may be identical to the first administration or may be treats human patients . In an embodiment , the human patient 
lower , e . g . a maintenance dose ) . In some embodiments , the is an infant . In an embodiment , the human patient is a 
further administration is about one day from the first admin - newborn . In another embodiment , the human patient is a 
istration , or about one week from the first administration . In neonate who is less than four weeks old , less than three 
some embodiments , the present methods provide for about 35 weeks old , less than two weeks old , less than one week old , 
1 - 3 ( e . g . about 1 , or about 2 , or about 3 ) doses ( e . g . IV doses less than six days old , less than five days old , less than four 
or IM doses ) of the antibodies of the present invention per days old , less than three days old , less than two days old , or 
week ( or about every 5 , or 6 , or 7 , or 10 days ) . In some less than one day old . In some embodiments , the human is 
embodiments , the present methods maintain a therapeutic one month old , two months old , three months old , four 
window of antibody levels in the blood serum of about 5 40 months old , five months old , or six months old . In some 
ug / mL , about 10 ug / mL , about 20 ug / mL , about 25 ug / mL , embodiments , the human has an age in a range of from about 
about 50 ug / mL , about 75 ug / mL , or about 100 ug / mL , or 6 to about 18 months old , from about 18 to about 36 months 
about 125 ug / mL , or about 150 ug / mL , or about 175 ug / mL , old , from about 1 to about 5 years old , from about 5 to about 
or about 200 ug / mL , or about 225 ug / mL , or about 250 10 years old , from about 10 to about 15 years old , from about 
ug / mL , or about 300 ug / mL . In some embodiments , the 45 15 to about 20 years old , from about 20 to about 25 years 
present methods allow for infrequent dosing and / or lower old , from about 25 to about 30 years old , from about 30 to 
dosing ( e . g . longer half - lives permitting lower and less about 35 years old , from about 35 to about 40 years old , from 
frequent dosing ) . about 40 to about 45 years old , from about 45 to about 50 
Either the humanized 1B7 antibody or the humanized years old , from about 50 to about 55 years old , from about 
11E6 antibody can be administered first . For example , the 50 55 to about 60 years old , from about 60 to about 65 years 
humanized 1B7 antibody can be administered to a subject old , from about 65 to about 70 years old , from about 70 to 
after the time at which the humanized 11E6 antibody is about 75 years old , from about 75 to about 80 years old , from 
administered . In this case , it is generally desirable to admin - about 80 to about 85 years old , from about 85 to about 90 
ister the humanized 1B7 antibody prior to the time at which years old , from about 90 to about 95 years old or from about 
about 50 % ( e . g . , prior to the time at which about 40 % , about 55 95 to about 100 years old . 
30 % , about 20 % , about 10 % , or about 5 % ) of the humanized In a further aspect , the method of the invention prevents 
11E6 antibody is metabolized or excreted by the subject , or Bordetella pertussis infection in a subject previously 
the time at which the humanized 11E6 antibody has reached exposed to the bacteria , comprising administering to the 
about 50 % , about 60 % , about 70 % , about 80 % , about 90 % , subject the humanized 1B7 antibody and / or the humanized 
or about 100 % of its pharmacodynamic activity . In another 60 11E6 antibody , or pharmaceutical compositions including 
example , the humanized 1B7 antibody can be administered the antibody or antibodies . In various embodiments , the 
to a subject before the administration of the humanized 11E6 method provides an effective prophylactic treatment in pre 
antibody . In this case , it is generally desirable to administer venting Bordetella pertussis infection in a subject exposed to 
the humanized 11 E6 antibody prior to the time at which the bacteria . 
about 50 % ( e . g . , prior to the time at which about 40 % , about 65 In some embodiments , the antibody of the invention ( e . g . , 
30 % , about 20 % , about 10 % , or about 5 % ) of the humanized humanized hulB7 antibody and / or hullE6 antibody ) is 
1B7 antibody is metabolized or excreted by the subject , or utilized in prophylactic applications in a subject who has not 
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been previously vaccinated against the bacteria . In an Bordetella parapertussis infection when the humanized 1B7 
embodiment , the antibody of the invention is administered antibody and / or the humanized 11E6 antibody is adminis 
to a subject as a prophylactic treatment prior to the subject tered to the patient at about 3 months after infection . In other 
receiving a pertussis vaccination . In various embodiments , embodiments , the methods of the invention are effective in 
the antibody of the invention is utilized in prophylactic 5 treating Bordetella pertussis infection and / or Bordetella 
treatments of a subject who is less than one year old , less parapertussis infection when the humanized 1B7 antibody 
than eleven months old , less than ten months old , less than and / or the humanized 11 E6 antibody is administered to the 
nine months old , less than eight months old , less than seven patient at about 2 months , about 1 month , about 4 weeks , months old , less than six months old , less than five months about 3 weeks , about 2 weeks , about 7 days , about 6 days , old , less than four months old , less than three months old , 10 about 5 days , about 4 days , about 3 days , about 2 days , or less than two months old , less than one month old , less than about 1 day after infection . In an embodiment , the human four weeks old , less than three weeks old , less than two 
weeks old , less than one week old , less than six days old , less ized 1B7 antibody and / or the humanized 11E6 antibody is administered to the patient on the day of infection . than five days old , less than four days old , less than three 
days old , less than two days old , or less than one day old . 15 10 As used herein , " treat , " " treating ” and “ treatment ” mean 
Accordingly , in some embodiments , the present methods the treatment of a disease in a mammal , e . g . , in a human . In 
involving bridging the time between birth and vaccination in various embodiments , this includes : ( a ) inhibiting the dis 
an infant patient . ease , i . e . , arresting its development and / or ( b ) relieving the 
In various embodiments , the methods of the invention disease , i . e . , causing regression of the disease state . 
treat or prevent Bordetella pertussis infection in a subject 20 Pharmaceutical Compositions and Administration 
previously vaccinated against the bacteria . In an embodi The pharmaceutical compositions of the invention can be 
ment , the subject is an infant or child vaccinated with Dtap administered for therapeutic or prophylactic treatment . For 
( e . g . , INFANRIX ( with three antigens , mostly pertussis such uses , an antibody preferably is combined with a phar 
toxin ( PT ) and FHA ) , TRIPEDIA ( which contains two maceutically acceptable carrier . As used herein , " pharma 
components , FHA and PT , in equal amounts ) and DAPTA - 25 ceutically acceptable carrier " means buffers , carriers , and 
CEL ( which contains five components , PT , FHA , pertactin , excipients suitable for use in contact with the tissues of 
and fimbriae types 2 and 3 ) ) . In another embodiment , the human beings and animals without excessive toxicity , irri 
subject is an adult vaccinated with the pertussis booster t ation , allergic response , or other problem or complication , 
vaccine Tdap ( e . g . BOOSTRIX ( with three pertussis anti - commensurate with a reasonable benefit / risk ratio . The 
gens ( PT , FHA , and pertactin ) in a reduced quantity com - 30 carrier ( s ) should be “ acceptable ” in the sense of being 
pared with INFANRIX ) and ADACEL ( with the same five compatible with the other ingredients of the formulations 
pertussis components as DAPTACEL but with a reduced and not deleterious to the recipient . Pharmaceutically 
quantity of PT ) . In other embodiments , the patient of the acceptable carriers include buffers , solvents , dispersion 
present invention may or may not have received any one of media , coatings , isotonic and absorption delaying agents , 
the following pertussis combination vaccines : PEDIARIX , 35 and the like , that are compatible with pharmaceutical admin 
PENTACEL , or KINRIX . istration . The use of such media and agents for pharmaceu 
It is contemplated that the humanized antibodies of the tically active substances is known in the art . 
invention may further function as adjuvant for vaccinations Pharmaceutical compositions containing antibodies , such 
such as DtaP or Tdap . Further , in various embodiments , the as those disclosed herein , can be presented in a dosage unit 
methods of the invention treat or prevent Bordetella pertus - 40 form and can be prepared by any suitable method . A 
sis infection in a subject that has not been previously pharmaceutical composition should be formulated to be 
vaccinated against the bacteria compatible with its intended route of administration . 
In various embodiments , the present compositions and Examples of routes of administration are oral , intranasal , 
methods supplement or supplant treatment with palivizumab pulmonary , intravenous ( IV ) , intradermal , inhalation , trans 
( SYNAGIS ) . 45 dermal , topical , transmucosal , subcutaneous , intramuscular 
In various embodiments , the present compositions and ( IM ) , intraperitoneal , and rectal administration . In an 
methods can treat pertussis infections that have various embodiment , the route of administration for antibodies of 
strains as their etiology , including , by way of non - limiting the invention is IV infusion . In another embodiment , the 
example , pertactin - negative pertussis . route of administration for antibodies of the invention is IM 
Furthermore , Bordetella parapertussis is a closely related 50 injection . 
species Bordetella pertussis . Both bacteria are linked to Useful formulations can be prepared by methods well 
outbreaks of whooping cough in humans and produce simi - known in the pharmaceutical art . For example , pharmaceu 
lar virulence factors . Co - infection of Bordetella pertussis tical compositions of the invention can be formulated as a 
and Bordetella parapertussis is not unusual . Accordingly , in colloidal dispersion system , macromolecular complex , 
one aspect of the invention , the method of the invention 55 nanocapsule , microsphere , bead , oil - in - water emulsion , 
involves treating a patient with Bordetella parapertussis , micelle , mixed micelle , or liposome . For example , see 
comprising administering to the patient the humanized 1B7 Remington ' s Pharmaceutical Sciences , 18th ed . ( Mack Pub 
antibody and / or the humanized 11E6 antibody , or pharma - lishing Company , 1990 ) . 
ceutical compositions including the antibody or antibodies . Formulation components suitable for parenteral adminis 
In another aspect of the invention , the method of the 60tration include a sterile diluent such as water for injection , 
invention prevents Bordetella parapertussis infection in a saline solution , fixed oils , polyethylene glycols , glycerine , 
subject previously exposed to the bacteria , comprising propylene glycol or other synthetic solvents ; antibacterial 
administering to the subject the humanized 1B7 antibody agents such as benzyl alcohol or methyl paraben ; antioxi 
and / or the humanized 11E6 antibody , or pharmaceutical dants such as ascorbic acid or sodium bisulfite ; chelating 
compositions including the antibody or antibodies . 65 agents such as EDTA ; buffers such as acetates , citrates or 
In various embodiments , the methods of the invention are phosphates ; and agents for the adjustment of tonicity such as 
effective in treating Bordetella pertussis infection and / or sodium chloride or dextrose . 
25 
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For intravenous administration , suitable carriers include 700 mg , from about 0 . 01 mg to about 650 mg , from about 
physiological saline , bacteriostatic water , Cremophor ELTM 0 . 01 mg to about 600 mg , from about 0 . 01 mg to about 550 
( BASF , Parsippany , N . J . ) or phosphate buffered saline mg , from about 0 . 01 mg to about 500 mg , from about 0 . 01 
( PBS ) . The carrier should be stable under the conditions of mg to about 450 mg , from about 0 . 01 mg to about 400 mg , 
manufacture and storage , and should be preserved against 5 from about 0 . 01 mg to about 350 mg , from about 0 . 01 mg 
microorganisms . The carrier can be a solvent or dispersion to about 300 mg , from about 0 . 01 mg to about 250 mg , from 
medium containing , for example , water , ethanol , polyol ( for about 0 . 01 mg to about 200 mg , from about 0 . 01 mg to about 
example , glycerol , propylene glycol , and liquid polyethey - 150 mg , from about 0 . 01 mg to about 100 mg , from about 
lene glycol ) , and suitable mixtures thereof . 0 . 1 mg to about 90 mg , from about 0 . 1 mg to about 80 mg , 
The compositions provided herein , alone or in combina - 10 from about 0 . 1 mg to about 70 mg , from about 0 . 1 mg to 
tion with other suitable components , can be made into about 60 mg , from about 0 . 1 mg to about 50 mg , from about 
aerosol formulations ( i . e . , " nebulized ” ) to be administered 0 . 1 mg to about 40 mg active ingredient , from about 0 . 1 mg 
via inhalation . Aerosol formulations can be placed into to about 30 mg , from about 0 . 1 mg to about 20 mg , from 
pressurized acceptable propellants , such as dichlorodifluo - about 0 . 1 mg to about 10 mg , from about 0 . 1 mg to about 5 
romethane , propane , nitrogen , and the like . 15 mg , from about 0 . 1 mg to about 3 mg , from about 0 . 1 mg to 
Pharmaceutical formulations preferably are sterile . Ster - about 1 mg per unit dosage form , or from about 5 mg to 
ilization can be accomplished , for example , by filtration about 80 mg per unit dosage form . For example , a unit 
through sterile filtration membranes . Where the composition dosage form can be about 0 . 01 mg , about 0 . 02 mg , about 
is lyophilized , filter sterilization can be conducted prior to or 0 . 03 mg , about 0 . 04 mg , about 0 . 05 mg , about 0 . 06 mg , 
following lyophilization and reconstitution . 20 about 0 . 07 mg , about 0 . 08 mg , about 0 . 09 mg , about 0 . 1 mg , 
The pharmaceutical preparation is preferably in unit dos - about 0 . 2 mg , about 0 . 3 mg , about 0 . 4 mg , about 0 . 5 mg , 
age form . In such form the preparation is subdivided into about 0 . 6 mg , about 0 . 7 mg , about 0 . 8 mg , about 0 . 9 mg , 
unit doses containing appropriate quantities of the active about 1 mg , about 2 mg , about 3 mg , about 4 mg , about 5 
component . The unit dosage form can be a packaged prepa mg , about 6 mg , about 7 mg , about 8 mg , about 9 mg about 
ration , the package containing discrete quantities of prepa - 25 10 mg , about 15 mg , about 20 mg , about 25 mg , about 30 
ration , such as packeted tablets , capsules , and powders in mg , about 35 mg , about 40 mg , about 45 mg , about 50 mg , 
vials or ampoules . Also , the unit dosage form can be a about 55 mg , about 60 mg , about 65 mg , about 70 mg , about 
capsule , tablet , cachet , or lozenge itself , or it can be the 75 mg , about 80 mg , about 85 mg , about 90 mg , about 95 
appropriate number of any of these in packaged form . The mg , about 100 mg , about 150 mg , about 200 mg , about 250 
composition can also contain other compatible therapeutic 30 mg , about 300 mg , about 350 mg , about 400 mg , about 450 
agents . For example , the composition may additionally mg , about 500 mg , about 550 mg , about 600 mg , about 650 
include antimicrobial agents described herein . mg , about 700 mg , about 750 mg , about 800 mg , about 850 
The combined administrations contemplates co - adminis - mg , about 900 mg , about 950 mg , or about 1 , 000 mg , 
tration , using separate formulations or a single pharmaceu - inclusive of all values and ranges therebetween . 
tical formulation , and consecutive administration in either 35 In one embodiment , the antibody ( e . g . , humanized hu1B7 
order , wherein preferably there is a time period while both antibody and / or hu11E6 antibody ) is administered at an 
( or all ) active agents simultaneously exert their biological amount of from about 0 . 01 mg to about 100 mg daily , an 
activities . In an embodiment , a pharmaceutical composition amount of from about 0 . 01 mg to about 1 , 000 mg daily from 
of the invention includes a formulation of the humanized about 0 . 01 mg to about 950 mg daily , from about 0 . 01 mg 
1B7 antibody . In another embodiment , a pharmaceutical 40 to about 900 mg daily , from about 0 . 01 mg to about 850 mg 
composition of the invention includes a formulation of the daily , from about 0 . 01 mg to about 800 mg daily , from about 
humanized 11E6 antibody . In a further embodiment , a 0 . 01 mg to about 750 mg daily , from about 0 . 01 mg to about 
pharmaceutical composition of the invention includes a 700 mg daily , from about 0 . 01 mg to about 650 mg daily , 
co - formulation of both the humanized 1B7 antibody and the from about 0 . 01 mg to about 600 mg daily , from about 0 . 01 
humanized 11E6 antibody . 45 mg to about 550 mg daily , from about 0 . 01 mg to about 500 
It will be appreciated that the actual dose of the antibodies mg daily , from about 0 . 01 mg to about 450 mg daily , from 
( e . g . , humanized hu1B7 antibody and / or hul1E6 antibody ) about 0 . 01 mg to about 400 mg daily , from about 0 . 01 mg 
to be administered according to the present invention will to about 350 mg daily , from about 0 . 01 mg to about 300 mg 
vary according to , for example , the particular dosage form daily , from about 0 . 01 mg to about 250 mg daily , from about 
and the mode of administration . Many factors that may 50 0 . 01 mg to about 200 mg daily , from about 0 . 01 mg to about 
modify the action of the antibodies ( e . g . , body weight , 150 mg daily , from about 0 . 1 mg to about 100 mg daily , from 
gender , diet , time of administration , route of administration , about 0 . 1 mg to about 95 mg daily , from about 0 . 1 mg to 
rate of excretion , condition of the subject , drug combina - about 90 mg daily , from about 0 . 1 mg to about 85 mg daily , 
tions , genetic disposition and reaction sensitivities ) can be from about 0 . 1 mg to about 80 mg daily , from about 0 . 1 mg 
taken into account by those skilled in the art . Administration 55 to about 75 mg daily , from about 0 . 1 mg to about 70 mg 
can be carried out continuously or in one or more discrete daily , from about 0 . 1 mg to about 65 mg daily , from about 
doses within the maximum tolerated dose . Optimal admin 0 . 1 mg to about 60 mg daily , from about 0 . 1 mg to about 55 
istration rates for a given set of conditions can be ascertained mg daily , from about 0 . 1 mg to about 50 mg daily , from 
by those skilled in the art using conventional dosage admin - about 0 . 1 mg to about 45 mg daily , from about 0 . 1 mg to 
istration tests . 60 about 40 mg daily , from about 0 . 1 mg to about 35 mg daily , 
Individual doses of the antibody ( e . g . , humanized hu1B7 from about 0 . 1 mg to about 30 mg daily , from about 0 . 1 mg 
antibody and / or hu11E6 antibody ) can be administered in to about 25 mg daily , from about 0 . 1 mg to about 20 mg 
unit dosage forms containing , for example , from about 0 . 01 daily , from about 0 . 1 mg to about 15 mg daily , from about 
mg to about 1 , 000 mg , from about 0 . 01 mg to about 950 mg , 0 . 1 mg to about 10 mg daily , from about 0 . 1 mg to about 5 
from about 0 . 01 mg to about 900 mg , from about 0 . 01 mg 65 mg daily , from about 0 . 1 mg to about 3 mg daily , from about 
to about 850 mg , from about 0 . 01 mg to about 800 mg , from 0 . 1 mg to about 1 mg daily , or from about 5 mg to about 80 
about 0 . 01 mg to about 750 mg , from about 0 . 01 mg to about mg daily . In various embodiments , the antibody is admin 
27 
US 10 , 035 , 846 B2 
28 
istered at a daily dose of about 0 . 01 mg , about 0 . 02 mg , embodiments , the antibody can be administered as a sus 
about 0 . 03 mg , about 0 . 04 mg , about 0 . 05 mg , about 0 . 06 tained release formulation , in which case less frequent 
mg , about 0 . 07 mg , about 0 . 08 mg , about 0 . 09 mg , about 0 . 1 administration is required . 
mg , about 0 . 2 mg , about 0 . 3 mg , about 0 . 4 mg , about 0 . 5 mg , In some methods , the antibody of the invention is admin 
about 0 . 6 mg , about 0 . 7 mg , about 0 . 8 mg , about 0 . 9 mg , 5 istered at a dosage to achieve a plasma or serum antibody 
about 1 mg , about 2 mg , about 3 mg , about 4 mg , about 5 concentration of 1 - 1000 ug / ml and in some methods 25 - 300 
mg about 6 mg about 7 mg about 8 mg about omg about mg , about 6 mg , about 7 mg , about 8 mg , about 9 mg about ug / ml . For example , the antibody of the invention can be 
10 mg , about 15 mg , about 20 mg , about 25 mg , about 30 administered at a dosage to achieve a plasma or serum level 
mg , about 35 mg , about 40 mg , about 45 mg , about 50 mg , of about 1 - 1000 ug / ml , 1 - 900 ug / ml , 1 - 800 ug / ml , 1 - 700 
about 55 mg , about 60 mg , about 65 mg , about 70 mg , about 10 ug / ml , 1 - 600 ug / ml , 1 - 500 ug / ml , 1 - 400 ug / ml , 1 - 300 ug / ml , 1 - 200 ug / ml , 1 - 100 ug / ml , 10 - 500 ug / ml , 10 - 400 ug / ml , 75 mg , about 80 mg , about 85 mg , about 90 mg , about 95 10 - 300 ug / ml , 10 - 200 ug / ml , 10 - 100 ug / ml , 100 - 400 ug / ml , mg , about 100 mg , about 150 mg , about 200 mg , about 250 100 - 300 ug / ml , or 100 - 200 ug / ml , inclusive of all values and mg , about 300 mg , about 350 mg , about 400 mg , about 450 ranges therebetween . For example , the antibody of the mg , about 500 mg , about 550 mg , about 600 mg , about 650 15 invention can be administered at a dosage to achieve a mg , about 700 mg , about 750 mg , about 800 mg , about 850 plasma or serum level of about 1 ug / ml , about 5 ug / ml , about 
mg , about 900 mg , about 950 mg , or about 1 , 000 mg 10 ug / ml , about 15 ug / ml , about 20 ug / ml , about 25 ug / ml , 
inclusive of all values and ranges therebetween about 30 ug / ml , about 35 ug / ml , about 40 ug / ml , about 45 
In some embodiments , a suitable dosage of the antibody ug / ml , about 50 ug / ml , about 55 ug / ml , about 60 ug / ml , 
( e . g . , humanized hu1B7 antibody and / or hu11E6 antibody ) 20 about 65 ug / ml , about 70 ug / ml , about 75 ug / ml , about 80 
is in a range of about 0 . 01 mg / kg to about 100 mg / kg of body ug / ml , about 85 ug / ml , about 90 ug / ml , about 95 ug / ml , 
weight of the subject , for example , about 0 . 01 mg / kg , about about 100 ug / ml , about 105 ug / ml , about 110 ug / ml , about 
0 . 02 mg / kg , about 0 . 03 mg / kg , about 0 . 04 mg / kg , about 0 . 05 115 ug / ml , about 120 mg ug / ml , about 125 ug / ml , about 130 
mg / kg , about 0 . 06 mg / kg , about 0 . 07 mg / kg , about 0 . 08 ug / ml , about 135 ug / ml , about 140 ug / ml , about 145 ug / ml , 
mg / kg , about 0 . 09 mg / kg , about 0 . 1 mg / kg , about 0 . 2 mg / kg , 25 about 150 ug / ml , about 155 ug / ml , about 160 ug / ml , about 
about 0 . 3 mg /kg , about 0 . 4 mg / kg , about 0 . 5 mg / kg , about 165 ug / ml , about 170 ug / ml , about 175 ug / ml , about 180 
0 . 6 mg / kg , about 0 . 7 mg / kg , about 0 . 8 mg / kg , about 0 . 9 ug / ml , about 185 ug / ml , about 190 ug / ml , about 195 ug / ml , 
mg / kg , about 1 mg / kg , about 1 . 1 mg / kg , about 1 . 2 mg / kg , about 200 ug / ml , about 205 ug / ml , about 210 ug / ml , about 
about 1 . 3 mg / kg , about 1 . 4 mg / kg , about 1 . 5 mg / kg , about 215 ug / ml , about 220 mg ug / ml , about 225 ug / ml , about 230 
1 . 6 mg / kg , about 1 . 7 mg / kg , about 1 . 8 mg / kg , 1 . 9 mg / kg , 30 ug / ml , about 235 ug / ml , about 240 ug / ml , about 245 ug / ml , 
about 2 mg / kg , about 3 mg / kg , about 4 mg / kg , about 5 about 250 ug / ml , about 255 ug / ml , about 260 ug / ml , about 
mg / kg , about 6 mg / kg , about 7 mg / kg , about 8 mg / kg , about 265 ug / ml , about 270 ug / ml , about 275 ug / ml , about 280 
9 mg / kg , about 10 mg / kg , about 15 mg / kg , about 20 mg / kg , ug / ml , about 285 ug / ml , about 290 ug / ml , about 295 ug / ml ,
about 25 mg / kg , about 30 mg / kg , about 35 mg /kg , about 40 or about 300 ug / ml . 
mg / kg , about 45 mg / kg , about 50 mg / kg , about 55 mg / kg , 35 In some methods , the antibody of the invention ( e . g . , 
about 60 mg / kg , about 65 mg / kg , about 70 mg / kg , about 75 humanized hulB7 antibody and / or hullE6 antibody ) 
mg / kg , about 80 mg / kg , about 85 mg / kg , about 90 mg / kg , or achieves a potency of at least about 1 EU / ug , at least about 
about 100 mg / kg body weight , inclusive of all values and 2 EU / ug , at least about 3 EU / ug , at least about 4 EU / ug , at 
ranges therebetween . In other embodiments , a suitable dos - least about 5 EU / ug , at least about 6 EU / ug , at least about 7 
age of the antibody in a range of about 0 . 01 mg / kg to about 40 EU / ug , at least about 8 EU / ug , at least about 9 EU / ug , at 
100 mg / kg of body weight , in a range of about 1 mg / kg to least about 10 EU / ug , at least about 15 EU / ug , at least about 
about 100 mg / kg of body weight , in a range of about 1 20 EU / ug , at least about 25 EU / ug , at least about 30 EU / ug , 
mg / kg to about 90 mg / kg of body weight , in a range of about at least about 35 EU / ug , at least about 40 EU / ug , at least 
1 mg / kg to about 80 mg / kg of body weight , in a range of about 45 EU / ug , at least about 50 EU / ug , at least about 55 
about 1 mg / kg to about 70 mg / kg of body weight , in a range 45 EU / ug , at least about 60 EU / ug , at least about 65 EU / ug , at 
of 1 mg / kg to about 60 mg / kg of body weight , in a range of least about 70 EU / ug , at least about 75 EU / ug , at least about 
1 mg / kg to about 50 mg / kg of body weight , in a range of 1 80 EU / ug , at least about 85 EU / ug , at least about 90 EU / ug , 
mg / kg to about 40 mg / kg of body weight , in a range of 1 at least about 95 EU / ug , at least or about 100 EU / ug . In some 
mg / kg to about 30 mg / kg of body weight , in a range of 1 methods , the antibody of the invention ( e . g . , humanized 
mg / kg to about 20 mg / kg of body weight , in a range of about 50 hu1B7 antibody and / or hu11E6 antibody ) achieves a 
5 mg / kg to about 50 mg / kg of body weight , in a range of potency of at least about 1 EU / ml , at least about 2 EU / ml , 
about 5 mg / kg to about 40 mg /kg of body weight , in a range at least about 3 EU / ml , at least about 4 EU / ml , at least about 
of about 5 mg / kg to about 30 mg / kg of body weight , in a 5 EU / ml , at least about 6 EU / ml , at least about 7 EU / ml , at 
range of about 5 mg / kg to about 20 mg / kg of body weight , least about 8 EU / ml , at least about 9 EU / ml , at least about 
inclusive of all values and ranges therebetween . 55 10 EU / ml , at least about 15 EU / ml , at least about 20 EU / ml ,
In accordance with certain embodiments of the invention , at least about 25 EU / ml , at least about 30 EU / ml , at least 
the antibody ( e . g . , humanized hu1B7 antibody and / or about 35 EU / ml , at least about 40 EU / ml , at least about 45 
hu11E6 antibody ) may be administered , for example , more EU / ml , at least about 50 EU / ml , at least about 55 EU / ml , at 
than once daily , about once per day , about every other day , least about 60 EU / ml , at least about 65 EU / ml , at least about 
about every third day , about once a week , about once every 60 70 EU / ml , at least about 75 EU / ml , at least about 80 EU / ml , 
two weeks , about once every month , about once every two at least about 85 EU / ml , at least about 90 EU / ml , at least 
months , about once every three months , about once every about 95 EU / ml , at least or about 100 EU / ml . EU stands for 
six months , or about once every year . equivalent units as defined by the WHO polyclonal serum 
Antibody can be administered on multiple occasions . standard . In various embodiments , the antibody of the 
Intervals between single dosages can be weekly , monthly or 65 invention is able to maintain potency after at least about 1 
yearly . Intervals can also be irregular as indicated by mea - day , about 2 days , about 3 days , about 4 days , about 5 days , 
suring blood levels of the antibody in the subject . In some about 6 days , about 1 week , about 2 weeks , about 3 weeks , 
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about 4 weeks , about 5 months , about 6 months , about 7 antibody with the mouse variable region followed by a 
months , about 8 months , about 9 months , about 10 months , human constant region . Specifically , the construct encoded 
about 11 months , or about 12 months . SEQ ID NO : 13 fused to a human IgG1 heavy chain constant 
Dosage and frequency vary depending on factors such as region . Similarly , an expression plasmid construct encoding 
route of administration , dosage amount , the disease being 5 a chimeric 11E6 light chain was generated . The construct 
treated , and the half - life of the antibody in the patient . The encoded SEQ ID NO : 19 fused to a human Kappa light chain 
dosage and frequency of administration can vary depending constant region . The two expression constructs also encoded 
on whether the treatment is prophylactic or therapeutic . In a promoter , 5 ' untranslated sequence , and heterologous 
prophylactic applications , a relatively low dosage is admin - signal peptide for expression in , and secretion from CHO 
istered at relatively infrequent intervals over a long period of 10 cells . 
time . In therapeutic applications , a relatively high dosage at In analogous fashion , four expression plasmids encoding 
relatively short intervals is sometimes required until pro humanized 11E6 heavy chains were constructed utilizing 
gression of the disease is reduced or terminated , and pref - SEQ ID NOs : 14 , 15 , 17 , and 18 . These were designated Hi , 
erably until the patient shows partial or complete ameliora - H2 , H3 , and H4 respectively . Three expression plasmids 
tion of symptoms of disease . Thereafter , the patient can be 15 encoding humanized 11E6 light chains were constructed 
administered a prophylactic regime . Illustrative dosing fre - utilizing SEQ ID NOs : 20 , 21 , and 23 . These were desig 
quencies are once per day , twice per day , three times per day , nated L1 , L2 , and L3 , respectively . 
once per week and once every two weeks . In some embodi The heavy and light chain chimeric expression plasmids 
ments , dosing is once every two weeks . were co - transfected into CHO cells , which then secreted 
The invention also provides kits that can simplify the 20 bivalent chimeric antibodies into the tissue culture medium . 
administration of any agent described herein ( e . g . the Similarly , all 12 combinations for the humanized heavy and 
humanized antibodies with or without various combination light chain constructs were co - transfected into CHO cells . 
agents ) . An illustrative kit of the invention comprises any Specifically , H1 was co - transfected with L1 , L2 , L3 , and L4 ; 
composition described herein in unit dosage form . In one H2 was co - transfected with L1 , L2 , L3 , and L4 ; and H3 was 
embodiment , the unit dosage form is a container , such as a 25 co - transfected with L1 , L2 , L3 , and L4 . Media was collected 
pre - filled syringe , which can be sterile , containing any agent from each transfection , antibody levels in the samples were 
described herein and a pharmaceutically acceptable carrier , quantified , and binding to pertussis toxin was determined by 
diluent , excipient , or vehicle . The kit can further comprise a ELISA . Both the chimeric constructs and all of the 12 
label or printed instructions instructing the use of any agent humanized combinations yielded antibodies that specifically 
described herein . The kit may also include a lid speculum , 30 bound pertussis toxin . H1 and H4 in combinations with L2 
topical anesthetic , and a cleaning agent for the administra - and L3 generated the highest ELISA signals . The combina 
tion location . The kit can also further comprise one or more tion of H4 and L3 was chosen for further evaluation . 
additional agent described herein . In one embodiment , the The dissociation constants ( Kd ) for the parental murine 
kit comprises a container containing an effective amount of antibody , the chimeric antibody , the H4 / L3 antibody were 
a composition of the invention and an effective amount of 35 determined with a pertussis toxin - binding competition assay . 
another composition , such those described herein . In this assay , increasing concentrations of pertussis toxin are 
In some embodiments , the kit ma comprises a pre - filled exposed to a constant amount of antibody . The amount of 
syringe in unit dose form ( e . g . an injector pen ) . In various unbound antibody remaining is then quantified by ELISA . 
embodiments , the kits are suited for use away from a The dissociation constants for the three antibodies were 
traditional medical center , e . g . in the field , e . g . in the third 40 nearly identical . 
world . Thus , the 11E6 antibody was humanized without any loss 
of affinity versus the parental murine antibody . 
EXAMPLES 
Example 2 
The following Examples are merely illustrative and are 45 
not intended to limit the scope or content of the invention in Screening and Evaluation of Humanized 1B7 
any way . Heavy and Light Chain Variable Regions 
Example 1 The same evaluation was performed with the 1B7 chime 
50 ric sequences as well as 20 combinations of humanized 1B7 
Screening and Evaluation of Humanized 11E6 heavy and light chains . Expression plasmids were generated 
Heavy and Light Chain Variable Regions encoding the 1B7 chimeric heavy and light chains , SEQ ID 
NOs : 1 and 7 , respectively . Expression plasmids for four 
An expression plasmid construct encoding a chimeric 1B7 humanized heavy chains were prepared encoding SEQ 
11E6 heavy chain was generated . The construct encoded an 55 ID NOs : 2 , 3 , 5 , and 6 , which were designated H1 , H2 , H3 , 
antibody with the mouse variable region followed by a H4 , respectively . Expression plasmids for five 1B7 human 
human constant region . Specifically , the construct encoded ized light chains were prepared encoding SEQ ID NOs : 8 , 9 , 
SEQ ID NO : 13 fused to a human IgG1 heavy chain constant 11 , 12 , and 10 , which were designated L1 , L2 , L3 , L4 , and 
region . Similarly , an expression plasmid construct encoding L5 respectively . For each expression plasmid the promoter , 
a chimeric 11E6 light chain was generated . The construct 60 5 ' untranslated region , signal peptide , and constant region 
encoded SEQ ID NO : 19 fused to a human Kappa light chain ( IgG1 and Kappa ) were the same as was used for the 11E6 
constant region . The two expression constructs also encoded constructs in Example 1 . 
a promoter , 5 ' untranslated sequence , and heterologous The chimeric heavy and light chain - encoding plasmids 
signal peptide for expression in , and secretion from CHO were co - transfected into CHO cells to generate a chimeric 
cells . 65 1B7 antibody . Plasmids for each combination of humanized 
An expression plasmid construct encoding a chimeric 1B7 heavy and light chain were also co - transfected into 
11E6 heavy chain was generated . The construct encoded an CHO cells to produce 20 different humanized 1B7 antibod 
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ies . The antibodies were then evaluated via the pertussis antibody and to 250 L for production of the hu11E6 anti 
toxin binding ELISA as was done with 11E6 in Example 1 . body . The upstream process utilized serum - free , chemically 
H1 and H2 in combinations with L3 and L4 produced the defined , and commercially available cell culture medium 
highest ELISA signals . H2 / L3 was the combination chosen and feeds . The downstream process utilized a three - step 
for further development . In the pertussis toxin competition 5 purification by sequential chromatography ( i . e . , protein - A , 
assay , the dissociation constants for the parental murine 1B7 anion exchange , and cation exchange ) . The manufacturing 
antibody and the H2 / L3 humanized 1B7 antibody were 0 . 15 process also included a detergent - based virus inactivation and 0 . 16 nM respectively . step and tangential flow filtration into a PBS formulation Thus , the 1B7 antibody was humanized without any loss buffer ( pH 7 . 0 ) at 10 mg / mL . The two antibody preparations of affinity versus the parental murine antibody . were sterilized through a 0 . 2 um filter and bulk filled into 
Example 3 high density polyethylene bottles . The purified preparations 
were stored long - term at < - 35° C . Yields of the humanized 
Construction of Humanized Antibodies that Bind hu1B7 and hu11E6 antibodies were 47 and 70 grams ,
the Pertussis Toxin Protein respectively . This yield is more than an order of magnitude 
higher compared to CHO cell manufacturing lines generated 
The two humanized antibodies identified in Examples 1 by standard plasmid transfection methods . 
and 2 , above , were produced in CHO cells . Specifically , for panel of bio - analytical assays was conducted for batch 
each antibody , two retroviral vectors were prepared , one analysis and stability studies of the manufactured antibodies . 
encoding the heavy chain and the second encoding the light 20 These methods included product - related tests such as A280 
chain . For each antibody , the pair of retroviral vectors was absorption reading , SDS - PAGE , SE - HPLC , IEF , and ELISA 
used to repeatedly transduce and genetically modify a non - activity assay , as well as process - related tests such as 
clonal pool of CHO cells . The recombinant CHO cells were analysis of host cell DNA and protein , endotoxin , bioburden , 
then grown in shake flasks for two weeks . Each antibody and mycoplasma . Appearance , osmolality , and pH were also 
was purified from the CHO cell tissue culture medium via a 25 measured . Both monoclonal antibodies exhibited superior 
Protein A column . The humanized hulB7 and hullE6 characteristics in these assays 
antibodies were analyzed using SDS - PAGE gel ( see FIGS . 
1 and 3 ) . In addition , the humanized hu1B7 and hu11E6 Example 5 
antibodies as well as a mixture of the two antibodies were 
also analyzed by size exclusion chromatography ( see FIGS . 30 Characterization of the Humanized Antibodies 2 , 4 , and 5 ) . Specifically , 500 uL of the antibodies in PBS 
( 100 ug / mL ) was incubated for 24 hour at 4° C . and the Thermal stability assays were used to assess the stability samples were run on a S200 column with PBS buffer . of the humanized hul1E6 and hu1B7 antibodies as well as The humanized hu1B7 and hu11E6 antibodies were ana 
lyzed using SDS - PAGE gel ( see FIGS . 1 and 3 ) . In addition , 35 " their murine counterparts , as shown FIGS . 6A - 6D . 
the humanized hu1B7 and hu11E6 antibodies as well as a An ELISA assay was performed to determine the ability of the humanized hul1E6 and hu1B7 antibodies to bind the mixture of the two antibodies were also analyzed by size 
exclusion chromatography ( see FIGS . 2 , 4 , and 5 ) . Specifi pertussis toxin protein ( see FIG . 7 ) . Specifically , the pertus 
cally , 500 uL of the antibodies in PBS ( 100 ug / mL ) was sis toxin protein was used for coating while anti - mouse - HRP 
incubated for 24 hour at 4° C . and the samples were run on 40 or anti - human FC - HRP were used as secondary antibodies . 
a 5200 column with PBS buffer . TMB ( 3 , 3 , 5 , 5 ' - Tetramethylbenzidine ) was used as sub 
The following results were obtained for the humanized strate for the assay . The following EC50 ( NM ) data was 
hu1B7 antibody : concentration : 5 . 78 mg / mL ( using an A280 obtained : 
absorbance coefficient of 1 . 64 ( mg / mL ) - 1 ) ; endotoxin of m1B7 : 0 . 19 + 0 . 01 ; 
< 0 . 25 EU / mL ( < 0 . 04 EU / mg ) ; and bioburden of < 0 . 2 CFU / 45 hu1B7A : 0 . 23 + 0 . 04 ; 
mL ( Pass ) . m11E6 : 2 . 7 + 0 . 7 ; and 
The following results were obtained for the humanized hu11E6A 1 . 320 . 2 . 
hu11E6 antibody : concentration : 5 . 62 mg / mL ( using an As indicated , the humanized hu11E6 and hu1B7 antibodies 
A280 absorbance coefficient of 1 . 56 ( mg / mL ) - 1 ) ; endotoxin exhibited high affinity for the pertussis toxin protein that is 
of < 0 . 25 EU / mL ( < 0 . 04 EU / mg ) ; and bioburden of < 0 . 2 50 either comparable to or superior to the murine antibodies . 
CFU / mL ( Pass ) . FIG . 8 shows the results of a Competition ELISA assay 
As shown in FIG . 5 , the antibody preparations exhibited which determines the binding affinities of the humanized 
no apparent aggregation . hulB7 and hu11E6 antibodies . The dissociation constants 
were assayed on antibody preparations generated in an Example 4 academic research lab compared to those generated at a 
Contract Research Organization ( CRO ) . For the ELISA , the 
Manufacturing of Humanized Antibodies pertussis toxin protein was used for coating while anti 
human Fc - HRP were used as a secondary antibody . TMB ( 3 , 
Large - scale manufacturing of the humanized hu1B7 and 3 ' , 5 , 59 - Tetramethylbenzidine ) was used as a substrate . 
hul1E6 antibodies was carried out . Specifically , the human - 60 The following Kd ( NM ) data were obtained : 
ized hu1B7 and hu11E6 antibodies were expressed in CHO Research lab hu1B7A = 1 . 7 + 0 . 2 : 
cells using retroviral transduction technology followed by a CRO hu1B7A 2 . 6 + 0 . 1 ; 
monoclonal antibody purification process . Clones and Research lab hu11E6A 10 . 7 + 0 . 3 ; and 
backup clones for producing each antibody were identified . CRO hu11E6A 11 . 3 + 0 . 4 . 
Each clone was characterized for expression , and the quality 65 The binding affinities of the humanized hu1B7 and 
of the resultant antibodies was verified . The upstream pro - hul1E6 antibodies were also measured by BIAcore , and the 
cess was scaled to 100 L for production of the hu1B7 following Kd data were obtained as shown in Table 1 . 






( nM ) ; 
n = x exp . 
Kd , 
BIAcore 
( NM ) 
( Chi2 ) 
On - rate , 
BIAcore 
( sec - ' M - 1 ) 
Off - rate , 
BIAcore 
( sec - ? ) 
Melting 
temp 
( °C . ) 
m1B7 0 . 4 + 0 . 2 74 . 8 + 0 . 7 
ch1B7 0 . 5 + + 0 . 3 
0 . 7 + 0 . 2 
( 0 . 32 ) 
0 . 5 + 0 . 4 
( 0 . 74 ) 
0 . 7 + 0 . 5 
( 0 . 75 ) 
0 . 2 + 0 . 2 * 
( 0 . 13 ) 
1 . 7 + 0 . 3 x 
105 
1 . 5 + 0 . 1 x 
105 
0 . 9 + 0 . 2 x 
1 . 2 + 0 . 3 x 
10 - 4 
0 . 8 + 0 . 5 x 
104 
0 . 7 0 . 5 x 
78 . 1 + 0 . 5 
hu1B7A 1 . 2 + 0 . 7 79 . 0 + 0 . 3 +
105 104 
m11E6 + 0 . 8 + 0 . 1 x 0 . 2 + 0 . 1 x 67 . 3 + 0 . 4 a 




?? 69 . 4 + 0 . 4 74 . 4 + 0 . 4 + 1 0 . 4 + 0 . 7 * 
( 0 . 26 ) 
0 . 65 + 0 . 05 * 
105 
0 . 3 0 . 4 x 
10 - 4 * 
A CHO cell in vitro protection assay was conducted to half - life of about 128 hours , while a mixture of the two 
compare the neutralization activity of the humanized hu1B7 20 antibodies had an elimination half - life of about 76 hours . 
and hu11E6 antibodies . The assays was performed by two An ELISA assay was conducted to determine whether different technicians ( see FIG . 9 ) . Specifically , this assay heat affected the binding affinities of the humanized hu1B7A measured the ability of the antibodies to neutralize the and hullE6A antibodies for the pertussis toxin protein ( see pertussis toxin protein . As shown in FIG . 9 , the humanized FIGS . 12 and 13 ) . The ELISA assay was performed as and mouse antibodies were comparable at neutralizing the 25 
pertussis toxin protein . previously described . Particularly , 50 ug / mL of the antibody 
A mixture of the humanized 11E6 and 1B7 antibodies was was incubated in PBS for 30 minutes on ice , at 50° C . , or at 
prepared by mixing the antibodies and storing at 4° C . for 1 70° C . and quenched on ice for 1 minute . As shown in FIG . 
minute , 1 hour , and 22 hours . The binding affinity of the 12 , the humanized hu1B7A antibody remained stable and 
mixture for the pertussis toxin protein was evaluated using 20 did not irreversibly unfold after 30 minutes of heating at 50° 
an ELISA assay as previously described ( see FIG . 10 ) . The v C . or 70° C . As shown in FIG . 13 , the humanized hu11E6A 
following EC - ( nM ) data was obtained : antibody remained stable after 30 minutes of heating at 50° 
1 minute = 0 . 12 + 0 . 02 ; C . but irreversibly unfolded after heating at 70° C . 
1 hour = 0 . 10 + 0 . 01 ; and An ELISA assay was conducted to compare the binding 
22 hours = 0 . 17 + 0 . 07 . 35 affinities of the individual humanized hu1B7A or hu11E6A 
As evidenced by the EC 50 data , there was no apparent antibody as compared to the mixture of the two antibodies 
adverse interaction between the humanized hu1B7 antibody ( see FIG . 14 ) . The ELISA assay was performed as previ 
and the humanized hu11E6 antibody upon storage as a ously described . The following EC50 ( NM ) data were 
mixture that would interfere with their binding affinities for obtained : 
the pertussis toxin protein . 40 hu1B7A : 0 . 09 + 0 . 01 ; Table 2 below summarizes a pharmacokinetic ( PK ) analy 
sis of the humanized hulB7 antibody as compared to the hu11E6A : 0 . 61 + 0 . 07 ; and 




( ug ) AUCOsco BmlB7 ( ug * hr / ml ) ( hr - 1 ) 
01 / 28 
( hr ) 
b 
( ug / ml ) 
Est . conc . @ 
t = 3 days 
( ug / ml ) 
Est . conc . @ Est . conc . @ 
t = 7 days t = 10 days 
( ug / 
1 
m1B7 1 * 0 . 28 
5 * 1 . 4 
20 * 
140 
107 . 9 
539 . 8 
2 , 159 
15 . 114 
25 7 
127 + 38 
509 + 149 
0 . 0033 
0 . 0033 
0 . 0033 
0 . 0033 
0 . 0078 
0 . 0078 
0 . 0078 
210 0 . 36 
210 1 . 8 
210 7 . 1 
210 49 . 9 
890 . 20 + 0 . 08 
89 1 . 0 + 0 . 4 
89 3 . 9 1 . 6 
0 . 21 
1 . 03 
4 . 1 
28 . 7 
0 . 05 + 0 . 02 
0 . 26 + 0 . 08 
1 . 0 0 . 3 
5 . 6 
39 . 3 
0 . 11 + 0 . 03 
0 . 6 + 0 . 2 
2 . 2 0 . 7 
0 . 16 
0 . 82 
3 . 2 
22 . 6 
0 . 03 + 0 . 01 
0 . 15 + 0 . 06 





From the PK analysis , it was determined that 5 ug of the Example 6 
murine m1B7 antibody fully protected mice infected with B . 
pertussis and had an elimination half - life of about 210 hours . Evaluation of the Humanized Antibodies in 
In comparison , 20 ug of the humanized hu1B7 had an ou Treating B . pertussis Infections in Mice 
elimination half - life of about 89 hours ( see FIG . 11 ) and had The efficacy of the humanized hu1B7 and hu11E6 anti a similar blood concentration through day 7 . Accordingly , bodies in treating B . pertussis infections was evaluated in a 
the 20 ug dose of the humanized hu1B7 antibody was mouse model . 
expected to protect infected mice in a similar manner to the 65 Specifically , mice infected with the B . pertussis D420 
5 ug dose of the murine m1B7 antibody . Further , as shown strain were treated with the humanized hu1B7 antibody , the 
in FIG . 10 , the humanized 11E6 antibody had an elimination humanized hu11E6 antibody , and a mixture of the two 
35 
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antibodies . The infected mice were subsequently analyzed nized . The other two treated animals were also euthanized . 
for their body weight and white blood cell count . As shown Histological evaluation of lung sections were performed . In 
in FIG . 15 , treatment with each humanized antibody sepa the second study , four baboons were infected with 4x109 
rately or in combination allowed for greater weight gain in CFU of B . pertussis and three days later , two of the animals 
the infected mice than those treated with PBS or with the 5 were treated with both the humanized hu1B7 and the 
murine m1B7 antibody . FIGS . 16A - 16B show that treatment humanized hu11E6 antibodies , and two animals remained 
with the humanized antibodies also significantly reduced the untreated . The antibodies were administered via intravenous 
white blood cell count of the infected mice at 3 and 10 days injection , and each was used at dose of 20 mg / kg . 
post infections . As shown in FIG . 18A , the untreated animal developed a 
The effect of antibody treatments on bacterial lung colo - 10 leukocytosis that peaked above 40 , 000 cells per uL . In this 
nization was also assessed . Specifically , mice were treated animal , the elevated white count persisted . Three weeks 
with either PBS , P - IVIG , the humanized hu1B7 antibody , after infection , the animal suddenly became moribund and 
the humanized hu11E6 antibody , or a mixture of the two was euthanized . In contrast , the white counts in the treated 
antibodies . Bacterial lung colonization was evaluated at 10 animals began to decrease within two days after antibody 
days postinfection . Uninfected naive mice served as the 15 administration . The counts continued to drop and were 
baseline control . Infected mice were euthanized by CO , nearly normal within one week . These animals remained 
inhalation on day 10 postinfections , and the respiratory tract healthy and were sacrificed in parallel with the untreated 
was excised for enumeration by serial plating on Regan animal . The cough counts displayed a similar pattern ( FIG . 
Lowe agar supplemented with 10 % sheep ' s blood ( Hemostat 18B ) . The control animal displayed a rapid increase in 
Resources ) containing 40 ug / ml cephalexin . Colonies were 20 coughing from Day 3 to the end of the study peaking at 5 
counted after 5 days at 37° C . As shown in FIG . 17 , mice days at over 50 coughs per hour . In contrast , the two treated 
treated with the antibodies displayed a significant drop in animals showed increasing coughing up to Day 3 ( treatment ) 
bacterial colonization compared to the untreated controls which rapidly declined to zero by Day 4 . 
( PBS ) or the P - IVIG - treated animals . P < 0 . 05 ( * ) for animals The lungs of the infected baboons were evaluated by 
treated with hu1B7 , and hu11E6 alone , and P < 0 . 01 ( * * ) for 25 histopathological examination ( FIG . 19 ) . At necropsy , the 
animals treated with the combination of hu1B7 and 11E6 . untreated animal was shown to have a consolidated right 
Altogether , these data supports the in vivo efficacy of the lung . Histopathology of this lung demonstrated severe sub 
humanized hu11E6 and hu1B7 antibodies in treating B . acute to chronic , diffuse interstitial pneumonia with abscess 
pertussis infection . formation and moderate interstitial fibrosis . The left lung 
30 revealed a more moderate interstitial pneumonia with much 
Example 7 less scarring and no evidence of abscess formation . There 
also was moderate chronic multifocal organizing pleuritis 
Evaluation of the Humanized Antibodies in with an area of abscess formation . In contrast , at necropsy , 
Treating B . pertussis Infections in Baboons the lungs of the two treated animals were grossly normal . 
35 Histopathology sections from the right lung of one treated 
The efficacy of the humanized hu1B7 and hul1E6 anti - animal revealed very mild chronic interstitial pneumonia 
bodies in treating B . pertussis infections was evaluated in a with evidence of very mild interstitial fibrosis . The left lung 
baboon model . was essentially normal in appearance . For the other treated 
Specifically , weanling ( 6 - 9 month old ) male and female animal the right and left lungs had an essentially normal 
baboons ( Papio anubus , olive baboons ) of about 2 - 3 kg in 40 appearance with the only finding being mild to moderate 
weight were infected by intranasal administration of the B . lymphoid hyperplasia of the bronchial associated lymphoid 
pertussis D420 strain and treated intravenously with the tissue ( BALT ) . Thus , the untreated animal demonstrated 
humanized hu1B7 and the humanized hu11E6 antibodies . changes of severe pneumonia , whereas the lungs of the 
The infected baboons were analyzed for clinical signs of treated animals were either normal or demonstrated very 
illness ( for example , coughing , weight and temperature ) , 45 mild pneumonia . 
white blood cell counts , and / or nasal carriage levels of B . The white blood cell counts and nasal bacterial counts of 
pertussis . the infected baboons were assessed ( FIGS . 20A and 20B ) . 
For the B . pertussis infection , a B . pertussis strain , D420 , The untreated animals developed a leukocytosis that peaked 
was suspended in PBS at 10 % - 1010 cfu / ml . One ml was well above 40 , 000 cells per uL . In these animals , the 
delivered via endotracheal tube to the top of the baboon 50 elevated white count persisted and was not normalized by 
trachea . 0 . 5 ml was delivered via an intranasal catheter to the Day 20 . In contrast , the two treated animals displayed an 
back of each naris . Baboons were then placed in a sitting elevated white blood cell count at the time of antibody 
position for 3 minutes . For the phlebotomy , < 5 ml of blood treatment on Day 3 , however , the white blood cell count 
was collected via venipuncture with a butterfly catheter and never reached levels observed with the untreated animals , 
was aliquoted into tubes for white blood cell determination 55 and by Day 20 , both treated animals white blood cell counts 
and serum separation . Throughout the study , the baboons had returned to normal levels . Similarly , the B . pertussis 
were anesthetized with an intramuscular injection of ket - bacterial cell counts in the nasal washes demonstrated a 
amine for activities including antibody infusions , B . pertus - similar amount of bacteria at Day 3 ( treatment ) . Following 
sis infection , blood draws , nasopharyngeal washes , and antibody treatment , the bacterial levels in the nose displayed 
clinical observations . These activities were combined when - 60 a rapid decline for the antibody cocktail treated animals , 
ever possible to minimize the use of anesthesia . while the bacterial counts in the nose of the two control 
Two studies were conducted . In one , three baboons were animals remained well above 10 cfu by Day 18 . 
each infected with 6x109 CFU of B . pertussis . Three days The serum concentration and half - life of the humanized 
later , two of the animals were treated with both the human hu1B7 and the humanized hu11E6 antibodies were also 
ized hu1B7 and the humanized hul1E6 antibodies , and the 65 measured . To measure the amounts of the humanized 1B7 
third animal remained untreated . Three weeks after infec - and 11E6 antibodies in the baboon serum following intra 
tion , the untreated animal became moribund and was eutha - venous administration of 20 mg / kg of each antibody , blood 
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37 38 
samples were collected at various time points , serum iso - Accordingly , the protective plasma level of the SYN - 005 
lated , and serum samples were used in the anti - pertussis cocktail is expected to be greater than 5 EU / ml . Specifically , 
toxin ( PTx ) ELISA as described previously in Example 4 . it is expected that a 40 mg / kg intramuscular dose of SYN 
Specifically , the pertussis toxin protein was used for coating 005 will provide a serum level of 100 - 130 ug / ml at one 
while anti - human Fc - HRP were used as secondary antibod - 5 month and 5 ug / ml at four months . Since SYN - 005 has a 
ies . TMB ( 3 , 3 , 5 , 5 ' - Tetramethylbenzidine ) was used as potency of 2 EU / ug , a serum level of 5 ug / ml is equivalent 
substrate for the assay . Two treated baboons were used for to 10 EU / ml , twice the level required by the WHO standard 
this analysis ( i . e . , baboon # 12913 and 15913 ) . FIG . 21A for prophylactic treatments . Further , the observation that one 
shows the antibody serum concentration of the humanized EU of SYN - 005 is seven - fold more potent than one EU of 
hu1B7 and the humanized hu11E6 antibodies as calculated 10 the WHO polyclonal standard provides an additional margin 
by the equation : to ensure ongoing prophylaxis at four months . 
Altogether , these data suggest that a single dose of SYN 
Serum Conc = ae - ot + be - ßt 005 will maintain plasma levels above the threshold required 
to protect newborns from pertussis for at least four months . 
FIG . 21B shows the antibody half - life of the humanized 15 
antibodies . INCORPORATION BY REFERENCE 
In summary , both humanized antibodies , either individu 
ally or in combination , mitigated the weight loss , leukocy . The entire disclosure of each of the patent documents and 
tosis , and pulmonary bacterial burdens in a mouse pertussis scientific articles referred to herein is incorporated by ref 
model . Moreover , in the baboon model , the combination of 20 erence for all purposes . 
antibodies reversed the course of the disease in both treated The publications discussed herein are provided solely for 
animals enabling them to rapidly recover with normal or their disclosure prior to the filing date of the present appli 
near - normal lung histology . These data support the clinical cation . Nothing herein is to be construed as an admission 
application of the humanized antibodies of the invention as that the present invention is not entitled to antedate such 
a means to diminish morbidity , long - term sequelae , and 25 publication by virtue of prior invention . 
mortality in children with pertussis . As used herein , all headings are simply for organization 
and are not intended to limit the disclosure in any manner . Example 8 The content of any individual section may be equally 
applicable to all sections 
Prophylactic Administration of Humanized 
Antibodies to Newborns EQUIVALENTS 
30 
The humanized hu1B7 and hu11E6 antibodies are admin - The invention may be embodied in other specific forms 
istered via intramuscular injection to newborns to provide without departing from the spirit or essential characteristics 
prophylactic treatment against pertussis via passive immu - 35 thereof . The foregoing embodiments are therefore to be 
nization . Since pertussis during the first four months of life considered in all respects illustrative rather than limiting on 
portends the highest risk for death or serious illness with the invention described herein . 
long - term sequelae , treatment at birth can protect children 
during this high risk period and / or until they are old enough Embodiments 
to receive a standard pertussis vaccine . This may be par - 40 
ticularly important in the developing world where the risk of Embodiments 
contracting pertussis is high , the disease kills 160 , 000 to Embodiment 1 . A humanized 1B7 antibody that binds a 
300 , 000 children annually , and newborns only see a physi - pertussis toxin protein , comprising an immunoglobulin 
cian once at birth . heavy chain variable region and an immunoglobulin light 
A cocktail of humanized hulB7 and hu11E6 antibodies 45 chain variable region , wherein the immunoglobulin heavy 
( aka SYN - 005 ) is expected to provide at least four months chain variable region comprises an amino acid sequence 
of prophylaxis due to its plasma half - life and potency . selected from SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID NO : 3 , 
The half - life of SYN - 005 is estimated based on pharma SEQ ID NO : 4 , SEQ ID NO : 5 , and SEQ ID NO : 6 ; and the 
cokinetic ( PK ) data obtained from baboon studies in con - immunoglobulin light chain variable region comprises an 
junction with data available for other antibodies adminis - 50 amino acid sequence selected from SEQ ID NO : 7 , SEQ ID 
tered as prophylactic treatments to newborns . Specifically , NO : 8 , SEQ ID NO : 9 , SEQ ID NO : 10 , SEQ ID NO : 11 , and 
SYN - 005 was shown to have a beta half - life in baboons of SEQ ID NO : 12 . 
11 days . Embodiment 2 . A humanized 1B7 antibody that binds a 
The potency of SYN - 005 was assessed vis - à - vis the pertussis toxin protein , comprising an immunoglobulin 
World Health Organization ' s ( WHO ' s ) polyclonal serum 55 heavy chain variable region and an immunoglobulin light 
standard routinely used to predict vaccine efficacy . The chain variable region selected from : ( a ) an immunoglobulin 
WHO potency is quantified in equivalent units ( EU ) , and 5 heavy chain variable region comprising the amino acid 
EU / ml is considered a protective level in humans . See sequence of SEQ ID NO : 2 , and an immunoglobulin light 
Storsaeter J . et al . ( 1998 ) , Vaccine , 16 ( 20 ) : 1907 - 16 . Spe - chain variable region comprising the amino acid sequence of 
cifically , the potency of SYN - 005 was determined to be 2 60 SEQ ID NO : 8 ; ( b ) an immunoglobulin heavy chain variable 
EU / ug . Moreover , in a CHO cell functional assay , an EU of region comprising the amino acid sequence of SEQ ID NO : 
SYN - 005 was shown to be approximately seven - fold more 3 , and an immunoglobulin light chain variable region com 
potent than an EU of the WHO polyclonal standard . Par - prising the amino acid sequence of SEQ ID NO : 9 ; ( c ) an 
ticularly , the two humanized antibodies in SYN - 005 were immunoglobulin heavy chain variable region comprising the 
capable of neutralizing pertussis toxin , whereas many of the 65 amino acid sequence of SEQ ID NO : 4 , and an immuno 
PTx - binding antibodies in a polyclonal setting did not globulin light chain variable region comprising the amino 
interfere with pertussis toxin function . acid sequence of SEQ ID NO : 10 ; ( d ) an immunoglobulin 
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heavy chain variable region comprising the amino acid Embodiment 13 . An expression vector containing the 
sequence of SEQ ID NO : 5 , and an immunoglobulin light nucleic acid of embodiment 11 . 
chain variable region comprising the amino acid sequence of Embodiment 14 . An expression vector containing the 
SEQ ID NO : 11 ; and ( e ) an immunoglobulin heavy chain nucleic acid of embodiment 12 . 
variable region comprising the amino acid sequence of SEQ5 Embodiment 15 . The expression vector of embodiment 
ID NO : 6 , and an immunoglobulin light chain variable 14 , further comprising the nucleic acid of embodiment 11 . 
region comprising the amino acid sequence of SEQ ID Embodiment 16 . A host cell comprising the expression 
NO : 12 . vector of embodiment 13 . 
Embodiment 3 . A humanized 11E6 antibody that binds a Embodiment 17 . A host cell comprising the expression 
pertussis toxin protein , comprising an immunoglobulin 10 vector of embodiment 14 . 
heavy chain variable region and an immunoglobulin light Embodiment 18 . A host cell comprising the expression 
chain variable region , wherein the immunoglobulin heavy vector of embodiment 15 . 
chain variable region comprises an amino acid sequence Embodiment 19 . The host cell of embodiment 17 , further 
selected from SEQ ID NO : 13 , SEQ ID NO : 14 , SEQ ID comprising the expression vector of embodiment 13 . 
NO : 15 , SEO ID NO : 16 , SEQ ID NO : 17 , and SEQ ID 15 Embodiment 20 . A method of producing a polypeptide 
NO : 18 ; and the immunoglobulin light chain variable region comprising an immunoglobulin heavy chain variable region 
comprises an amino acid sequence selected from SEQ ID or an immunoglobulin light chain variable region , the 
NO : 19 , SEQ ID NO : 20 , SEQ ID NO : 21 , SEQ ID NO : 22 , method comprising : ( a ) growing the host cell of embodiment 
SEQ ID NO : 23 , and SEQ ID NO : 24 . 16 or 17 under conditions so that the host cell express the 
Embodiment 4 . A humanized 11E6 antibody that binds a 20 polypeptide comprising the immunoglobulin heavy chain 
pertussis toxin protein , comprising an immunoglobulin variable region or the immunoglobulin light chain variable 
heavy chain variable region and an immunoglobulin light region ; and ( b ) purifying the polypeptide comprising the 
chain variable region selected from : ( a ) an immunoglobulin immunoglobulin heavy chain variable region or the immu 
heavy chain variable region comprising the amino acid noglobulin light chain variable region . 
sequence of SEQ ID NO : 14 , and an immunoglobulin light 25 Embodiment 21 . A method of producing an antibody that 
chain variable region comprising the amino acid sequence of binds a pertussis toxin protein , the method comprising : ( a ) 
SEQ ID NO : 20 ; ( b ) an immunoglobulin heavy chain vari - growing the host cell of embodiment 18 or 19 under con 
able region comprising the amino acid sequence of SEQ ID ditions so that the host cell expresses a polypeptide com 
NO : 15 , and an immunoglobulin light chain variable region prising the immunoglobulin heavy chain variable region 
comprising the amino acid sequence of SEQ ID NO : 21 ; ( C ) 30 and / or the immunoglobulin light chain variable region , 
an immunoglobulin heavy chain variable region comprising thereby producing the antibody ; and ( b ) purifying the anti 
the amino acid sequence of SEQ ID NO : 16 , and an body . 
immunoglobulin light chain variable region comprising the Embodiment 22 . A pharmaceutical composition compris 
amino acid sequence of SEQ ID NO : 22 ; ( d ) an immuno - ing one or more antibodies of any one of embodiments 1 - 10 , 
globulin heavy chain variable region comprising the amino 35 and a pharmaceutically acceptable excipient . 
acid sequence of SEQ ID NO : 17 , and an immunoglobulin Embodiment 23 . The pharmaceutical composition of 
light chain variable region comprising the amino acid embodiment 22 , comprising the humanized 1B7 antibody of 
sequence of SEQ ID NO : 23 ; and ( e ) an immunoglobulin any one of embodiment 1 , 2 , 5 , 7 , or 8 and the humanized 
heavy chain variable region comprising the amino acid 1156 antibody of any one of embodiment 3 , 4 , 6 , 9 or 10 . 
sequence of SEQ ID NO : 18 , and an immunoglobulin light 40 Embodiment 24 . The pharmaceutical composition of 
chain variable region comprising the amino acid sequence of embodiment 23 , wherein the composition is formulated as a 
SEQ ID NO : 24 . colloidal dispersion system , macromolecular complex , 
Embodiment 5 . The antibody of embodiment 1 or 2 , nanocapsule , microsphere , bead , oil - in - water emulsion , 
wherein the antibody binds the pertussis toxin protein with micelle , mixed micelle , or liposome . 
a K , of 3 nM or lower . 45 Embodiment 25 . The pharmaceutical composition of any 
Embodiment 6 . The antibody of embodiment 3 or 4 , one of embodiments 22 - 24 , wherein the composition is 
wherein the antibody binds the pertussis toxin protein with formulated for oral , intranasal , pulmonary , intradermal , 
a K , of 12 nM or lower . transdermal , subcutaneous , intramuscular , intraperitoneal , 
Embodiment 7 . A humanized 1B7 antibody that binds a or intravenous delivery . 
pertussis toxin protein , wherein the antibody binds the 50 Embodiment 26 . A method of treating a patient infected 
pertussis toxin protein with a K , of 3 nM or lower . with Bordetella pertussis , comprising administering to the 
Embodiment 8 . The antibody of embodiment 7 , wherein patient the antibody of any of embodiments 1 - 10 or the 
the K , is about 3 nM , or about 2 nM , or about 1 nM , or about pharmaceutical composition of any one of embodiments 
0 . 5 nM . 22 - 25 . 
Embodiment 9 . A humanized 11E6 antibody that binds a 55 Embodiment 27 . A method of treating a patient infected 
pertussis toxin protein , wherein the antibody binds the with Bordetella pertussis , comprising co - administering to 
pertussis toxin protein with a Ky of 12 nM or lower . lower the patient an effective amount of the humanized 1B7 
Embodiment 10 . The antibody of embodiment 9 , wherein antibody of any one of embodiments 1 , 2 , 5 , 7 , or 8 and an 
the K , is about 12 nM , or about 10 nM , or about 8 nM , or effective amount of the humanized 11E6 antibody of any one 
about 6 nM , or 4 nM , or 2 nM , or about 1 nM , or about 0 . 5 60 of embodiment 3 , 4 , 6 , 9 or 10 . 
nM . Embodiment 28 . The method of embodiment 27 , wherein 
Embodiment 11 . An isolated nucleic acid comprising a the humanized 1B7 antibody and the humanized 11E6 
nucleotide sequence encoding an immunoglobulin heavy antibody are administered simultaneously to the patient . 
chain variable region of any one of embodiments 1 - 10 . Embodiment 29 . The method of embodiment 27 , wherein 
Embodiment 12 . An isolated nucleic acid comprising a 65 the humanized 1B7 antibody is administered to the patient 
nucleotide sequence encoding an immunoglobulin light prior to administering the humanized 11E6 antibody to the 
chain variable region of any one of embodiments 1 - 10 . patient . 
42 
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Embodiment 30 . The method of embodiment 27 , wherein chain variable region comprises an amino acid sequence 
the humanized 1B7 antibody is administered to the patient selected from SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID NO : 3 , 
after administering the humanized 11E6 antibody to the SEQ ID NO : 4 , SEQ ID NO : 5 , and SEQ ID NO : 6 ; and the 
patient . immunoglobulin light chain variable region comprises an 
Embodiment 31 . The method of embodiment 27 , wherein 5 amino acid sequence selected from SEQ ID NO : 7 , SEQ ID 
co - administration of the humanized 1B7 antibody and the NO : 8 , SEQ ID NO : 9 , SEQ ID NO : 10 , SEQ ID NO : 11 , and 
humanized 11E6 antibody produces synergistic effects . SEO ID NO : 12 . 
Embodiment 32 . A method of treating a patient infected Embodiment 2 . A humanized 1B7 antibody that binds a 
with Bordetella pertussis , comprising co - administering to pertussis toxin protein , comprising an immunoglobulin 
the patient at least one antibody of any one of embodiments 10 heavy chain variable region and an immunoglobulin light 
1 - 10 or the pharmaceutical composition of any one of chain variable region selected from : ( a ) an immunoglobulin 
embodiments 22 - 25 , and an antimicrobial agent . heavy chain variable region comprising the amino acid 
Embodiment 33 . The method of embodiment 33 , wherein sequence of SEQ ID NO : 2 , and an immunoglobulin light 
the antimicrobial agent is selected from azithromycin , chain variable region comprising the amino acid sequence of 
clarithromycin , erythromycin , trimethoprim - sulfamethoxas - 15 SEQ ID NO : 8 ; ( b ) an immunoglobulin heavy chain variable 
ole , roxithromycin , ketolides , ampicillin , amoxicillin , tetra - region comprising the amino acid sequence of SEQ ID NO : 
cycline , chloramphenicol , fluoroquinolones , and cepha - 3 , and an immunoglobulin light chain variable region com 
losporins . prising the amino acid sequence of SEQ ID NO : 9 ; ( c ) an 
Embodiment 34 . The method of any one of embodiments immunoglobulin heavy chain variable region comprising the 
26 - 33 , wherein the patient is human . 20 amino acid sequence of SEQ ID NO : 4 , and an immuno 
Embodiment 35 . The method of embodiment 34 , wherein globulin light chain variable region comprising the amino 
the human is an infant . acid sequence of SEQ ID NO : 10 ; ( d ) an immunoglobulin 
Embodiment 36 . A method of preventing Bordetella per - heavy chain variable region comprising the amino acid 
tussis infection in a subject previously exposed to Bordetella sequence of SEQ ID NO : 5 , and an immunoglobulin light 
pertussis , comprising administering to the subject an effec - 25 chain variable region comprising the amino acid sequence of 
tive amount of the antibody of any of embodiments 1 - 10 or SEQ ID NO : 11 ; and ( e ) an immunoglobulin heavy chain 
an effective amount of the pharmaceutical composition of variable region comprising the amino acid sequence of SEQ 
any one of embodiments 22 - 25 . ID NO : 6 , and an immunoglobulin light chain variable 
Embodiment 37 . The method of any one of embodiments region comprising the amino acid sequence of SEQ ID 
26 - 36 , wherein the method comprises a reduction of white 30 NO : 12 . 
blood cell count . Embodiment 3 . A humanized 11E6 antibody that binds a 
Embodiment 38 . The method of any one of embodiments pertussis toxin protein , comprising an immunoglobulin 
26 - 37 , wherein the method comprises a reduction of the heavy chain variable region and an immunoglobulin light 
duration and / or the frequency of cough . chain variable region , wherein the immunoglobulin heavy 
Embodiment 39 . The method of any one of embodiments 35 chain variable region comprises an amino acid sequence 
26 - 38 , wherein the method comprises a reduction of Bor selected from SEQ ID NO : 13 , SEQ ID NO : 14 , SEQ ID 
detella pertussis level in the nasopharynx and / or the lung . NO : 15 , SEQ ID NO : 16 , SEQ ID NO : 17 , and SEQ ID 
Embodiment 40 . The method of any one of embodiments NO : 18 ; and the immunoglobulin light chain variable region 
26 - 39 , wherein the pertussis toxin protein is neutralized . comprises an amino acid sequence selected from SEO ID 
Embodiment 41 . The method of embodiment 40 , wherein 40 NO : 19 , SEQ ID NO : 20 , SEQ ID NO : 21 , SEQ ID NO : 22 , 
the pertussis toxin protein is prevented from binding to its SEQ ID NO : 23 , and SEQ ID NO : 24 . 
cellular receptor . Embodiment 4 . A humanized 11E6 antibody that binds a 
Embodiment 42 . The method of embodiment 40 , wherein pertussis toxin protein , comprising an immunoglobulin 
the pertussis toxin protein is prevented from reaching the heavy chain variable region and an immunoglobulin light 
cellular cytosol . 45 chain variable region selected from : ( a ) an immunoglobulin 
Embodiment 43 . A method of treating a patient infected heavy chain variable region comprising the amino acid 
with Bordetella parapertussis , comprising administering to sequence of SEQ ID NO : 14 , and an immunoglobulin light 
the patient an effective amount of the antibody of any of chain variable region comprising the amino acid sequence of 
embodiments 1 - 10 or an effective amount of the pharma - SEQ ID NO : 20 ; ( b ) an immunoglobulin heavy chain vari 
ceutical composition of any one of embodiments 22 - 25 . 50 able region comprising the amino acid sequence of SEQ ID 
Embodiment 44 . A method of treating a patient infected NO : 15 , and an immunoglobulin light chain variable region 
with Bordetella parapertussis , comprising co - administering comprising the amino acid sequence of SEQ ID NO : 21 ; ( c ) 
to the patient an effective amount of the humanized 1B7 an immunoglobulin heavy chain variable region comprising 
antibody of any one of embodiments 1 , 2 , 5 , 7 , or 8 and an the amino acid sequence of SEQ ID NO : 16 , and an 
effective amount of the humanized 11E6 antibody of any one 55 immunoglobulin light chain variable region comprising the 
of embodiment 3 , 4 , 6 , 9 or 10 . amino acid sequence of SEQ ID NO : 22 ; ( d ) an immuno 
Embodiment 45 . A method of preventing Bordetella globulin heavy chain variable region comprising the amino 
parapertussis infection in a subject previously exposed to acid sequence of SEQ ID NO : 17 , and an immunoglobulin 
Bordetella pertussis , comprising administering to the sub - light chain variable region comprising the amino acid 
ject an effective amount of the antibody of any of embodi - 60 sequence of SEQ ID NO : 23 ; and ( e ) an immunoglobulin 
ments 1 - 10 or the pharmaceutical composition of any one of heavy chain variable region comprising the amino acid 
embodiments 22 - 25 . sequence of SEQ ID NO : 18 , and an immunoglobulin light 
P1 Embodiments : chain variable region comprising the amino acid sequence of 
Embodiment 1 . A humanized 1B7 antibody that binds a SEQ ID NO : 24 . 
pertussis toxin protein , comprising an immunoglobulin 65 Embodiment 5 . The antibody of embodiment 1 or 2 , 
heavy chain variable region and an immunoglobulin light wherein the antibody binds the pertussis toxin protein with 
chain variable region , wherein the immunoglobulin heavy a Ky of 3 nM or lower . 
44 
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Embodiment 6 . The antibody of embodiment 3 or 4 , Embodiment 25 . The pharmaceutical composition of any 
wherein the antibody binds the pertussis toxin protein with one of embodiments 22 - 24 , wherein the composition is 
a Ky of 12 nM or lower . formulated for oral , intranasal , pulmonary , intradermal , 
Embodiment 7 . A humanized 1B7 antibody that binds a transdermal , subcutaneous , intramuscular , intraperitoneal , 
pertussis toxin protein , wherein the antibody binds the 5 or intravenous delivery . 
pertussis toxin protein with a K , of 3 nM or lower . Embodiment 26 . A method of treating a patient infected 
Embodiment 8 . The antibody of embodiment 6 , wherein with Bordetella pertussis , comprising administering to the 
the Ky is about 3 nM , or about 2 nM , or about 1 nM , or about patient the antibody of any of embodiments 1 - 10 or the 
0 . 5 nM . pharmaceutical composition of any one of embodiments 
Embodiment 9 . A humanized 11E6 antibody that binds a " 22 - 25 . 
pertussis toxin protein , wherein the antibody binds the Embodiment 27 . A method of treating a patient infected 
pertussis toxin protein with a K , of 12 nM or lower . with Bordetella pertussis , comprising co - administering to 
Embodiment 10 . The antibody of embodiment 9 , wherein the patient the humanized 1B7 antibody of any one of 
the Ky is about 12 nM , or about 10 nM , or about 8 nM , or 15 embodiments 1 , 2 , 5 , 7 , or 8 and the humanized 11E6 
about 6 nM , or 4 nM , or 2 nM , or about 1 nM , or about 0 . 5 antibody of any one of embodiment 3 , 4 , 6 , 9 or 10 . 
nM . Embodiment 28 . The method of embodiment 27 , wherein 
Embodiment 11 . An isolated nucleic acid comprising a the humanized 1B7 antibody and the humanized 1156 
nucleotide sequence encoding an immunoglobulin heavy antibody are administered simultaneous to the patient . 
chain variable region of any one of embodiments 1 - 10 . 20 Embodiment 29 . The method of embodiment 27 , wherein 
Embodiment 12 . An isolated nucleic acid comprising a the humanized 1B7 antibody is administered to the patient 
nucleotide sequence encoding an immunoglobulin light prior to administering the humanized 11E6 antibody to the 
chain variable region of any one of embodiments 1 - 10 . patient . 
Embodiment 13 . An expression vector containing the Embodiment 30 . The method of embodiment 27 , wherein 
nucleic acid of embodiment 11 . 25 the humanized 1B7 antibody is administered to the patient 
Embodiment 14 . An expression vector containing the after administering the humanized 11E6 antibody to the 
nucleic acid of embodiment 12 . patient . 
Embodiment 15 . The expression vector of embodiment Embodiment 31 . The method of embodiment 27 , wherein 
14 , further comprising the nucleic acid of embodiment 11 . co - administration of the humanized 1B7 antibody and the 
Embodiment 16 . A host cell comprising the expression 30 humanized 11E6 antibody produces synergistic effects . 
vector of embodiment 13 . Embodiment 32 . A method of treating a patient infected 
Embodiment 17 . A host cell comprising the expression with Bordetella pertussis , comprising co - administering to 
vector of embodiment 14 . the patient at least one antibody of any one of embodiments 
Embodiment 18 . A host cell comprising the expression 1 - 10 or the pharmaceutical composition of any one of 
vector of embodiment 15 . 35 embodiments 22 - 25 , and an antimicrobial agent . 
Embodiment 19 . The host cell of embodiment 17 , further Embodiment 33 . The method of embodiment 33 , wherein 
comprising the expression vector of embodiment 13 . the antimicrobial agent is selected from azithromycin , 
Embodiment 20 . A method of producing a polypeptide clarithromycin , erythromycin , trimethoprim - sulfamethoxas 
comprising an immunoglobulin heavy chain variable region ole , roxithromycin , ketolides , ampicillin , amoxicillin , tetra 
or an immunoglobulin light chain variable region , the 40 cycline , chloramphenicol , fluoroquinolones , and cepha 
method comprising : ( a ) growing the host cell of embodiment losporins . 
16 or 17 under conditions so that the host cell express the Embodiment 34 . The method of any one of embodiments 
polypeptide comprising the immunoglobulin heavy chain 26 - 33 , wherein the patient is human . 
variable region or the immunoglobulin light chain variable Embodiment 35 . The method of embodiment 34 , wherein 
region ; and ( b ) purifying the polypeptide comprising the 45 the human is an infant . 
immunoglobulin heavy chain variable region or the immu - Embodiment 36 . A method of preventing Bordetella per 
noglobulin light chain variable region . tussis infection in a subject previously exposed to Bordetella 
Embodiment 21 . A method of producing an antibody that pertussis , comprising administering to the subject the anti 
binds a pertussis toxin protein , the method comprising : ( a ) body of any of embodiments 1 - 10 or the pharmaceutical 
growing the host cell of embodiment 18 or 19 under con - 50 composition of any one of embodiments 22 - 25 . 
ditions so that the host cell expresses a polypeptide com - Embodiment 37 . The method of any one of embodiments 
prising the immunoglobulin heavy chain variable region 26 - 36 , wherein the method comprises a reduction of white 
and / or the immunoglobulin light chain variable region , blood cell count . 
thereby producing the antibody ; and ( b ) purifying the anti Embodiment 38 . The method of any one of embodiments 
body . 55 26 - 37 , wherein the method comprises a reduction of the 
Embodiment 22 . A pharmaceutical composition compris - duration and / or the frequency of cough . 
ing the antibody of any one of embodiments 1 - 10 , and a Embodiment 39 . The method of any one of embodiments 
pharmaceutically acceptable excipient . 26 - 38 , wherein the method comprises a reduction of Bor 
Embodiment 23 . The pharmaceutical composition of detella pertussis level in the nasopharynx and / or the lung . 
embodiment 22 , comprising the humanized 1B7 antibody of 60 Embodiment 40 . The method of any one of embodiments 
any one of embodiment 1 , 2 , 5 , 7 , or 8 and the humanized 26 - 39 , wherein the pertussis toxin protein is neutralized . 
11E6 antibody of any one of embodiment 3 , 4 , 6 , 9 or 10 . Embodiment 41 . The method of embodiment 40 , wherein 
Embodiment 24 . The pharmaceutical composition of the pertussis toxin protein is prevented from binding to its 
embodiment 23 , wherein the composition is formulated as a cellular receptor . 
colloidal dispersion system , macromolecular complex , 65 Embodiment 42 . The method of embodiment 40 , wherein 
nanocapsule , microsphere , bead , oil - in - water emulsion , the pertussis toxin protein is prevented from reaching the 
micelle , mixed micelle , or liposome . cellular cytosol . 
US 10 , 035 , 846 B2 
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Embodiment 43 . A method of treating a patient infected Embodiment 45 . A method of preventing Bordetella 
with Bordetella parapertussis , comprising administering to parapertussis infection in a subject previously exposed to 
the patient the antibody of any of embodiments 1 - 10 or the Bordetella pertussis , comprising administering to the sub 
pharmaceutical composition of any one of embodiments ject the antibody of any of embodiments 1 - 10 or the phar 
22 - 25 . 5 maceutical composition of any one of embodiments 22 - 25 . Embodiment 44 . A method of treating a patient infected 
with Bordetella parapertussis , comprising co - administering Embodiment 46 . A composition as disclosed herein . 
to the patient the humanized 1B7 antibody of any one of Embodiment 47 . The use of any composition described 
embodiments 1 , 2 , 5 , 7 , or 8 and the humanized 11E6 herein one or more of : treatment of pertussis and manufac 
antibody of any one of embodiment 3 , 4 , 6 , 9 or 10 . ture of a medicament for the treatment of pertussis . 
SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 24 
A 
A 
< 210 > SEQ ID No 1 
1 > LENGTH : 118 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
20 > FEATURE : 








< 400 > SEQUENCE : 1 
Gin Val Gin Leu Gin Gin Pro Gly Ser Glu Leu Val Arg Pro Gly Ala 
10 
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr 
& 
g &
Trp Met His Trp Val Lys Gin Arg Pro Gly Gin Gly Leu Glu Trp Ile 
Gly Asn Ile Phe Pro Gly Ser Gly Ser Thr Asn Tyr Asp Glu Lys Phe am mmm Asn Ser Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Asn Thr Ala Tyr a ggg & Met Gin Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys ? Thr Arg Trp Leu Ser Gly Ala Tyr Phe Asp Tyr Trp Gly Gin Gly Thr 3 ? 
Thr Leu Thr Val Ser Ser 
5 
< 210 > SEQ ID NO 2 
1 > LENGTH : 118 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
1 21 230
< 400 > SEQUENCE : 2 | 
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
|
. 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr 
25 301 86 ED g g &Trp Met His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Ile 40 45 
Gly Asn Ile Phe Pro Gly Ser Gly Ser Thr Asn Tyr Asp Glu Lys Phe 
50 mam Asn Ser Ara Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 6g 2 2 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys mm ? Thr Arg Trp Leu Ser Gly Ala Tyr Phe Asp Tyr Trp Gly Gin Gly Thr 105 110 ?? 
US 10 , 035 , 846 B2 
- continued 
Thr Val Thr Val Ser Ser 
115 
< 210 > SEQ ID No 3 
< 211 > LENGTH : 118 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
< 400 > SEOUENCE : 3 
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr 
25 
Trp Met His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Ile 
40 mmm 3sm am 5mm me 
23? ?
Gly Asn Ile Phe Pro Gly Ser Gly Ser Thr Asn Tyr Ala Gin Lys Phe 
55 
% 
EEEE EEE gg Gin Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 70 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
Thr Arg Trp Leu Ser Gly Ala Tyr Phe Asp Tyr Trp Gly Gin Gly Thr 
105 
? ? Thr Val Thr Val Ser Ser 
115 
1 1 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 118 
< 212 > TYPE : PRT 
13 ) ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
< 400 > SEQUENCE : 4 
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr 
20 25 30 am Trp Met His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Ile 35 
? 
? IT 0EA g &
3 8?
g 
Gly Asn Ile Phe Pro Gly Ser Gly Ser Thr Asn Tyr Ala Gln Lys Phe ms mmm . Gin Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 75 70 RE Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 Thr Arg Trp Leu Ser Gly Ala Tyr Phe Asp Tyr Trp Gly Gin Gly Thr 100 105 110 E 1 Thr Val Thr Val Ser Ser 115 
V 
V 
< 210 > SEQ ID NO 5 
< 211 > LENGTH : 118 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
3 > OTHER INFORMATION : Synthetic 
V 
V 2 0 
ypeptide v 2 3
US 10 , 035 , 846 B2 
49 50 
- continued 
< 400 > SEQUENCE : 5 
Gin Val Gin Leu Gin Gin Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 
Phe Thr ser TY Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr 30 83? 9 Trp Met His Trp Val Lys Gin Arg Pro Gly Gin Gly Leu Glu Trp Ile 35 40 mam 3mm mam 
8g &
2 3??
EA ?A ? Gly Asn Ile Phe Pro Gly Ser Gly Ser Thr Asn Tyr Asp Glu Lys Phe 
& 3? EEE E ? Asn Ser Ara Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 70 8 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
Thr Arg Trp Leu Ser Gly Ala Tyr Phe Asp Tyr Trp Gly Gin Gly Thr 
3105 110 
| 
Thr Leu Thr Val Ser Ser 
115 
. 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 118 
< 212 > TYPE : PRT 
ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
A 13 > 
< 400 > SEQUENCE : 6 
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
& ?
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr 
25 30 





33? 3 2 ? 3 gg 8? 28Gly Asn Ile Phe Pro Gly Ser Gly Ser Thr Asn Tyr Asp Glu Lys Phe mmm Asn Ser Lys Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 3? & Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Trp Leu Ser Gly Ala Tyr Phe Asp Tyr Trp Gly Gin Gly Thr 105 110 ?Thr Leu Thr Val Ser Ser 115 
< 210 > SEQ ID No 7 
< 211 > LENGTH : 106 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 7 
Gin Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 
15 Leu Thr Gin ser Pro Ala Leu Met ser Ala Ser Pro Giy 1 
Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Phe Met 
20 25 30 ER Tyr Trp Tyr Gin Gin Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Tyr 35 45 40 
US 10 , 035 , 846 B2 
- continued 
Leu Thr Ser Asn Leu Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
50 55 60 
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
80 
? ?? BEAsp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser His Pro Pro Thr 
95 
Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
100 105 
< 210 > SEQ ID No 8 
< 211 > LENGTH : 106 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 122 ???? 
< 400 > SEQUENCE : 8 




? E RE mm Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Phe Met 30 20 
Tyr Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Lys Pro Leu Ile Tyr 
35 msm Leu Thr Ser Asn Leu Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 55 RED Gly Ser Gly Thr Ser Tyr Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu 70 mms . R Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser His Pro Pro Thr 85 95 Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
100 ? 
< 210 > SEO ID NO 9 
< 211 > LENGTH : 106 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide AAAA 2 31 220 3
< 400 > SEQUENCE : 9 





3 Glu Lys Val Thr Ile Thr Cys Arq Ala Ser Ser Ser Val Ser Phe Met 
20 25 
Tyr Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Lys Pro Leu Ile Tyr 
? 66Leu Thr Ser Asn Leu Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser mmm 55 &Rae Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu ?70 80 8 Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser His Pro Pro Thr 85 95 Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 100 105 
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 106 
< 212 > TYPE : PRT 
US 10 , 035 , 846 B2 
53 54 
- continued 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
< 400 > SEQUENCE : 10 
Gin Ile Val Leu Thr Gin Ser Pro Asp Phe Gin Ser Val Thr Pro Lys 
15 |
Glu Lys Val Thr Ile Thr Cys Arq Ala Ser Ser Ile Val Ser Phe Leu 
20 30 & 25 
Tyr Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Pro Leu Ile Tyr Tyr Trp Tyr Gin Gin Lys Pro Asp Gin ? EET R Leu Ala Ser Asn Leu Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 55 50 Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu 70 Thr Leu Thr Ile Agn 
Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser His Pro Pro Thr 
95 
Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
100 105 
< 210 > SEO ID NO 11 
< 211 > LENGTH : 106 
< 212 > TYPE : PRT 
ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
A 13 > 
< 400 > SEQUENCE : 11 
Gln Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
10 mm Glu Arq Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Phe Met 20 




? Gly Ser Gly Thr Ser Tyr Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu 
80 pg 2
Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser His Pro Pro Thr 
95 
Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
100 
AAAA 
< 210 > SEQ ID NO 12 
< 211 > LENGTH : 106 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
NN HAHowse 
< 400 > SEQUENCE : 12 
Gln Ile Val Leu Thr Gln Ser Pro Asp Phe Met Ser Ala Thr Pro Gly 
15 
?
9 ? . ?
Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Phe Met 
20 25 
Tyr Trp Tyr Gin Gin Lys Pro Arg Gin Ser Pro Lys Pro Trp Ile Tyr HEgg 2 Leu Thr Ser Asn Leu Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
55 m
US 10 , 035 , 846 B2 
55 56 
- continued 
? Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Asn Ser Met Glu Ala Glu 
65 75 80 Gly ser Gly Thr Asp Tyr 
Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser His Pro Pro Thr 
901 95 85 
333 Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 
< 210 > SEO ID NO 13 
< 211 > LENGTH : 123 
< 212 > TYPE : PRT | 
< 213 > ORGANI SM : Artificial sequence 
< 2202 FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
1 22
< 400 > SEQUENCE : 13 
Glu Val Lys Val Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 
15 
Ser Leu Arg Leu Ser Cys Thr Thr Ser Gly Phe Thr Phe Thr Asp Tyr E
30 




Leu Tyr Leu Gin Met Asn Thr Leu Arg Val Glu Asp Ser Ala Thr Tyr 
95 8 
g Tyr Cys Ala Arg Val Ser Tyr Tyr Gly Arg Gly Trp Tyr Phe Asp Tyr 
110 
Trp Gly Gin Gly Thr Thr Leu Thr Val Ser Ser 
115 120 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 123 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide AAAA 2 31 220 3
< 400 > SEQUENCE : 14 
Glu Val Gin Val Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Arg g ?
Ser Leu Arg Leu Ser Cys Thr Thr Ser Gly Phe Thr Phe Thr Asp Tyr 
20 30 




3 asm ?1? 6 gggGly Phe Ile Arg Asn Lys Val Asn Gly Tyr Thr Thr Glu Phe Ser Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Ile 
70 | 
Leu Tyr Leu Gin Met Asn Ser Leu Lys Ile Glu Asp Thr Ala Val Tyr 
3 Tyr Cys Ala Arg Val Ser Tyr Tyr Gly Arg Gly Trp Tyr Phe Asp Tyr 
100 110 
Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser 
115 
?
US 10 , 035 , 846 B2 
57 58 
- continued 
< 210 > SEO ID NO 15 
< 211 > LENGTH : 123 
< 212 > TYPE : PRT 
3 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 




< 400 > SEQUENCE : 15 
Glu Val Gin Val Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Arg 
5 
- ESer Leu Arg Leu Ser Cys Thr Thr Ser Gly Phe Thr Phe Thr Asp Tyr ?
20 30 




TEL : ma Gly Phe Ile Arg Asn Lys Val Asn Gly Tyr Thr Thr Glu Phe Ala Ala Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Ile 70 ng E mas mmmm Leu Tyr Leu Gin Met Asn Ser Leu Lys Ile Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ser Tyr Tyr Gly Arg Gly Trp Tyr Phe Asp Tyr 100 110 1? | Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser 
115 120 
1 
< 210 > SEQ ID NO 16 
< 211 > LENGTH : 123 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 16 
Glu Val Gin Val Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Arg &
Ser Leu Arg Leu Ser Cys Thr Thr Ser Gly Phe Thr Phe Thr Asp Tyr 
30 
Tyr Val Ser Trp Val Arg Gin Ala Pro Gly Lys Ala Leu Glu Trp Val 
35 mmm mm m? Gly Phe Ile Arg Asn Lys Val Asn Gly Tyr Thr Thr Glu Phe Ala Ala TEme 8Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Ile 70 g1 8R Leu Tyr Leu Gin Met Asn Ser Leu Lys Ile Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ser Tyr Tyr Gly Arg Gly Trp Tyr Phe Asp Tyr 
110 
Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser 
115 
1 1 
1 2 AAAA 
< 210 > SEQ ID NO 17 
< 211 > LENGTH : 123 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
20 > FEATURE : 




< 400 > SEQUENCE : 17 
Glu Val Gin Val Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 
15 10 
US 10 , 035 , 846 B2 
- continued 
| 
? Ser Leu Arg Leu Ser Cys Thr Thr Ser Gly Phe Thr Phe Thr Asp Tyr 
8 









Gly Phe Ile Arg Asn Lys Val Asn Gly Tyr Thr Thr Glu Phe Ser Ser 
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr m? g g 6gLeu Tyr Leu Gin Met Asn Thr Leu Arg Val Asp Asp Thr Ala Val Tyr 85 
E Tyr Cys Ala Arg Val Ser Tyr Tyr Gly Arg Gly Trp Tyr Phe Asp Tyr 





< 210 > SEQ ID NO 18 
< 211 > LENGTH : 123 
< 212 > TYPE : PRT | 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
< 400 > SEQUENCE : 18 
Glu Val Gin Val Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Arg 
|








Gly Phe Ile Arg Asn Lys Val Asn Gly Tyr Thr Thr Glu Phe Ser Ser 
55 
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Ile 
&T
EE am mmmm mm * sm 70 Leu Tyr Leu Gin Met Asn Ser Leu Lys Ile Glu Asp Thr Ala Val Tyr 85 Tyr Cys Ala Arg Val Ser Tyr Tyr Gly Arg Gly Trp Tyr Phe Asp Tyr 105 Trp Gly Gin Gly Thr Thr Leu Thr Val Ser Ser 115 120 
AAAA 
< 210 > SEQ ID NO 19 
< 211 > LENGTH : 107 
< 212 > TYPE : PRT 
213 5 ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
< 400 > SEQUENCE : 19 
Asp Ile Val Met Thr Gin Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly 
15 ? g
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gin Asp Ile Asp Asn Tyr 
25 18 oe3
Leu Ser Trp Phe Gin Gin Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
40 mas mms Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 55 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Leu Asp Gin 
US 10 , 035 , 846 B2 
- continued 
65 70 75 800 
Glu Asp Ile Ala Thr Tyr Phe Cys Gin Gin Gly Asn Thr Phe Pro Trp 
85 901 95 
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
100 105 
AAAA 
< 210 > SEQ ID NO 20 
< 211 > LENGTH : 107 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 





< 400 > SEQUENCE : 20 
Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
? 
g 
E Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gin Asp Ile Asp Asn Tyr 
20 25 
? E
Leu Ser Trp Phe Gin Gin Lys Pro Gly Gly Thr Val Lys Leu Leu Ile 
Tyr Tyr Thr Ser Ara Leu His Ser Gly Val Pro Ser Ara Phe Ser Gly 
& 
?3?
55 ? gggE g 8g
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
80 
Glu Asp Ile Ala Thr Tyr Phe Cys Gin Gin Gly Asn Thr Phe Pro Trp &
| | 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
< 210 > SEQ ID NO 21 
< 211 > LENGTH : 107 
< 212 > TYPE : PRT 
ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
A 2 1 3 
< 400 > SEQUENCE : 21 
Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Asp Ile Asp Asn Tyr 
20 25 
?
& Rng3 3? 83
& 
Rmws Leu Ser Trp Phe Gin Gin Lys Pro Gly Gly Thr Val Lys Leu Leu Ile 3 40 Tyr Tyr Thr Ser Arq Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly ggg 
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gin Pro 
g 2 
Glu Asp Ile Ala Thr Tyr Phe Cys Gin Gin Gly Asn Thr Phe Pro Trp 
95 
| 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
< 210 > SEQ ID NO 22 
< 211 > LENGTH : 107 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
1 2303 2 
< 400 > SEQUENCE : 22 
US 10 , 035 , 846 B2 
63 64 
- continued 
Rap Ile val Met pher sin ser Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 









Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
55 
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gin Pro mam 8 Glu Asp Ile Ala Thr Tyr Phe Cys Gin Gin Gly Asn Thr Phe Pro Trp 95 ;Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 ? ?1 
1 
1 
< 210 > SEQ ID NO 23 
< 211 > LENGTH : 107 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
1 2
< 400 > SEQUENCE : 23 
Asp Ile Val Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
o 
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gin Asp Ile Asp Asn Tyr 
20 25 
3 
Leu Ser Trp Phe Gin Gin Lys Pro Gly Gly Thr Val Lys Leu Leu Ile 
40 
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly gggg Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gin Pro 70 ?ae 3 & Glu Asp Ile Ala Thr Tyr Phe Cys Gin Gin Gly Asn Thr Phe Pro Trp 
? 
. 
Thr Phe Gly Gly Gly Thr Lys 
100 105 
1 2 
< 210 > SEQ ID NO 24 
< 211 > LENGTH : 107 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypept ide 
1 3 
AAA 2 0 2 3 
< 400 > SEQUENCE : 24 
Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gin Asp Ile Asp Asn Tyr 
25 ma gggg am Leu Ser Trp Phe Gin Gin Lys Pro Gly Gly Thr Val Lys Leu Leu Ile 35 40 gg & Ep3?Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gin Pro 
70 
US 10 , 035 , 846 B2 
65 
- continued 
Glu Asp Ile Ala Thr Tyr Phe Cys Gin Gin Gly Asn Thr Phe Pro Trp 
85 85 - 90 95 
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
100 105 
What is claimed is : 10 2 . The humanized 11E6 antibody of claim 1 , wherein the 
1 . A humanized 11E6 antibody that binds a pertussis toxin immunoglobulin heavy chain variable region comprises the 
protein , comprising an immunoglobulin heavy chain vari - amino acid sequence of SEO ID NO : 18 and the immuno 
able region and an immunoglobulin light chain variable globulin light chain variable region comprises the amino 
region , wherein acid sequence of SEQ ID NO : 23 . the immunoglobulin heavy chain variable region com - 15 3 . The humanized 11E6 antibody of claim 1 , wherein the prises an amino acid sequence selected from SEQ ID antibody binds the pertussis toxin protein with a Ky of 12 NO : 13 , SEQ ID NO : 14 , SEQ ID NO : 15 , SEQ ID nM or lower . NO : 16 , SEQ ID NO : 17 , or SEQ ID NO : 18 ; and 4 . A pharmaceutical composition comprising the human the immunoglobulin light chain variable region comprises 
an amino acid sequence selected from SEQ ID NO : 19 , 2012 ized 11E6 antibody of claim 1 , and a pharmaceutically 
SEQ ID NO : 20 , SEQ ID NO : 21 , SEQ ID NO : 22 , SEQ C acceptable excipient . 
ID NO : 23 , or SEQ ID NO : 24 . * * * * * 
